Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Inhibition of the Mitochondrial Enzyme ABAD Restores the Amyloid-β-Mediated Deregulation of Estradiol</title><author><name sortKey="Lim, Yun An" sort="Lim, Yun An" uniqKey="Lim Y" first="Yun-An" last="Lim">Yun-An Lim</name><affiliation><nlm:aff id="aff1"><addr-line>Alzheimer's & Parkinson's Disease Laboratory, Brain & Mind Research Institute, University of Sydney, Camperdown, New South Wales, Australia</addr-line></nlm:aff></affiliation></author><author><name sortKey="Grimm, Amandine" sort="Grimm, Amandine" uniqKey="Grimm A" first="Amandine" last="Grimm">Amandine Grimm</name><affiliation><nlm:aff id="aff2"><addr-line>Neurobiology Laboratory, Psychiatric University Clinics Basel, University of Basel, Basel, Switzerland</addr-line></nlm:aff></affiliation></author><author><name sortKey="Giese, Maria" sort="Giese, Maria" uniqKey="Giese M" first="Maria" last="Giese">Maria Giese</name><affiliation><nlm:aff id="aff2"><addr-line>Neurobiology Laboratory, Psychiatric University Clinics Basel, University of Basel, Basel, Switzerland</addr-line></nlm:aff></affiliation></author><author><name sortKey="Mensah Nyagan, Ayikoe Guy" sort="Mensah Nyagan, Ayikoe Guy" uniqKey="Mensah Nyagan A" first="Ayikoe Guy" last="Mensah-Nyagan">Ayikoe Guy Mensah-Nyagan</name><affiliation><nlm:aff id="aff3"><addr-line>Equipe Steroïdes, Neuromodulateurs et Neuropathologies, Université de Strasbourg, Strasbourg, France</addr-line></nlm:aff></affiliation></author><author><name sortKey="Villafranca, J Ernest" sort="Villafranca, J Ernest" uniqKey="Villafranca J" first="J. Ernest" last="Villafranca">J. Ernest Villafranca</name><affiliation><nlm:aff id="aff4"><addr-line>Villafranca Consulting, San Diego, California, United States of America</addr-line></nlm:aff></affiliation></author><author><name sortKey="Ittner, Lars M" sort="Ittner, Lars M" uniqKey="Ittner L" first="Lars M." last="Ittner">Lars M. Ittner</name><affiliation><nlm:aff id="aff1"><addr-line>Alzheimer's & Parkinson's Disease Laboratory, Brain & Mind Research Institute, University of Sydney, Camperdown, New South Wales, Australia</addr-line></nlm:aff></affiliation></author><author><name sortKey="Eckert, Anne" sort="Eckert, Anne" uniqKey="Eckert A" first="Anne" last="Eckert">Anne Eckert</name><affiliation><nlm:aff id="aff2"><addr-line>Neurobiology Laboratory, Psychiatric University Clinics Basel, University of Basel, Basel, Switzerland</addr-line></nlm:aff></affiliation></author><author><name sortKey="Gotz, Jurgen" sort="Gotz, Jurgen" uniqKey="Gotz J" first="Jürgen" last="Götz">Jürgen Götz</name><affiliation><nlm:aff id="aff1"><addr-line>Alzheimer's & Parkinson's Disease Laboratory, Brain & Mind Research Institute, University of Sydney, Camperdown, New South Wales, Australia</addr-line></nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">22174920</idno><idno type="pmc">3236223</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236223</idno><idno type="RBID">PMC:3236223</idno><idno type="doi">10.1371/journal.pone.0028887</idno><date when="2011">2011</date><idno type="wicri:Area/Pmc/Corpus">002C32</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">002C32</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Inhibition of the Mitochondrial Enzyme ABAD Restores the Amyloid-β-Mediated Deregulation of Estradiol</title><author><name sortKey="Lim, Yun An" sort="Lim, Yun An" uniqKey="Lim Y" first="Yun-An" last="Lim">Yun-An Lim</name><affiliation><nlm:aff id="aff1"><addr-line>Alzheimer's & Parkinson's Disease Laboratory, Brain & Mind Research Institute, University of Sydney, Camperdown, New South Wales, Australia</addr-line></nlm:aff></affiliation></author><author><name sortKey="Grimm, Amandine" sort="Grimm, Amandine" uniqKey="Grimm A" first="Amandine" last="Grimm">Amandine Grimm</name><affiliation><nlm:aff id="aff2"><addr-line>Neurobiology Laboratory, Psychiatric University Clinics Basel, University of Basel, Basel, Switzerland</addr-line></nlm:aff></affiliation></author><author><name sortKey="Giese, Maria" sort="Giese, Maria" uniqKey="Giese M" first="Maria" last="Giese">Maria Giese</name><affiliation><nlm:aff id="aff2"><addr-line>Neurobiology Laboratory, Psychiatric University Clinics Basel, University of Basel, Basel, Switzerland</addr-line></nlm:aff></affiliation></author><author><name sortKey="Mensah Nyagan, Ayikoe Guy" sort="Mensah Nyagan, Ayikoe Guy" uniqKey="Mensah Nyagan A" first="Ayikoe Guy" last="Mensah-Nyagan">Ayikoe Guy Mensah-Nyagan</name><affiliation><nlm:aff id="aff3"><addr-line>Equipe Steroïdes, Neuromodulateurs et Neuropathologies, Université de Strasbourg, Strasbourg, France</addr-line></nlm:aff></affiliation></author><author><name sortKey="Villafranca, J Ernest" sort="Villafranca, J Ernest" uniqKey="Villafranca J" first="J. Ernest" last="Villafranca">J. Ernest Villafranca</name><affiliation><nlm:aff id="aff4"><addr-line>Villafranca Consulting, San Diego, California, United States of America</addr-line></nlm:aff></affiliation></author><author><name sortKey="Ittner, Lars M" sort="Ittner, Lars M" uniqKey="Ittner L" first="Lars M." last="Ittner">Lars M. Ittner</name><affiliation><nlm:aff id="aff1"><addr-line>Alzheimer's & Parkinson's Disease Laboratory, Brain & Mind Research Institute, University of Sydney, Camperdown, New South Wales, Australia</addr-line></nlm:aff></affiliation></author><author><name sortKey="Eckert, Anne" sort="Eckert, Anne" uniqKey="Eckert A" first="Anne" last="Eckert">Anne Eckert</name><affiliation><nlm:aff id="aff2"><addr-line>Neurobiology Laboratory, Psychiatric University Clinics Basel, University of Basel, Basel, Switzerland</addr-line></nlm:aff></affiliation></author><author><name sortKey="Gotz, Jurgen" sort="Gotz, Jurgen" uniqKey="Gotz J" first="Jürgen" last="Götz">Jürgen Götz</name><affiliation><nlm:aff id="aff1"><addr-line>Alzheimer's & Parkinson's Disease Laboratory, Brain & Mind Research Institute, University of Sydney, Camperdown, New South Wales, Australia</addr-line></nlm:aff></affiliation></author></analytic><series><title level="j">PLoS ONE</title><idno type="eISSN">1932-6203</idno><imprint><date when="2011">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Alzheimer's disease (AD) is a conformational disease that is characterized by amyloid-β (Aβ) deposition in the brain. Aβ exerts its toxicity in part by receptor-mediated interactions that cause down-stream protein misfolding and aggregation, as well as mitochondrial dysfunction. Recent reports indicate that Aβ may also interact directly with intracellular proteins such as the mitochondrial enzyme ABAD (Aβ binding alcohol dehydrogenase) in executing its toxic effects. Mitochondrial dysfunction occurs early in AD, and Aβ's toxicity is in part mediated by inhibition of ABAD as shown previously with an ABAD decoy peptide. Here, we employed AG18051, a novel small ABAD-specific compound inhibitor, to investigate the role of ABAD in Aβ toxicity. Using SH-SY5Y neuroblastoma cells, we found that AG18051 partially blocked the Aβ-ABAD interaction in a pull-down assay while it also prevented the Aβ42-induced down-regulation of ABAD activity, as measured by levels of estradiol, a known hormone and product of ABAD activity. Furthermore, AG18051 is protective against Aβ42 toxicity, as measured by LDH release and MTT absorbance. Specifically, AG18051 reduced Aβ42-induced impairment of mitochondrial respiration and oxidative stress as shown by reduced ROS (reactive oxygen species) levels. Guided by our previous finding of shared aspects of the toxicity of Aβ and human amylin (HA), with the latter forming aggregates in Type 2 diabetes mellitus (T2DM) pancreas, we determined whether AG18051 would also confer protection from HA toxicity. We found that the inhibitor conferred only partial protection from HA toxicity indicating distinct pathomechanisms of the two amyloidogenic agents. Taken together, our results present the inhibition of ABAD by compounds such as AG18051 as a promising therapeutic strategy for the prevention and treatment of AD, and suggest levels of estradiol as a suitable read-out.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Gotz, J" uniqKey="Gotz J">J Gotz</name></author><author><name sortKey="Ittner, Lm" uniqKey="Ittner L">LM Ittner</name></author><author><name sortKey="Schonrock, N" uniqKey="Schonrock N">N Schonrock</name></author><author><name sortKey="Cappai, R" uniqKey="Cappai R">R Cappai</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Small, Dh" uniqKey="Small D">DH Small</name></author><author><name sortKey="Mok, Ss" uniqKey="Mok S">SS Mok</name></author><author><name sortKey="Bornstein, Jc" uniqKey="Bornstein J">JC Bornstein</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="David, Dc" uniqKey="David D">DC David</name></author><author><name sortKey="Ittner, Lm" uniqKey="Ittner L">LM Ittner</name></author><author><name sortKey="Gehrig, P" uniqKey="Gehrig P">P Gehrig</name></author><author><name sortKey="Nergenau, D" uniqKey="Nergenau D">D Nergenau</name></author><author><name sortKey="Shepherd, C" uniqKey="Shepherd C">C Shepherd</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hoerndli, F" uniqKey="Hoerndli F">F Hoerndli</name></author><author><name sortKey="David, D" uniqKey="David D">D David</name></author><author><name sortKey="Gotz, J" uniqKey="Gotz J">J Gotz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lin, H" uniqKey="Lin H">H Lin</name></author><author><name sortKey="Bhatia, R" uniqKey="Bhatia R">R Bhatia</name></author><author><name sortKey="Lal, R" uniqKey="Lal R">R Lal</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cappai, R" uniqKey="Cappai R">R Cappai</name></author><author><name sortKey="Barnham, Kj" uniqKey="Barnham K">KJ Barnham</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Roberson, Ed" uniqKey="Roberson E">ED Roberson</name></author><author><name sortKey="Scearce Levie, K" uniqKey="Scearce Levie K">K Scearce-Levie</name></author><author><name sortKey="Palop, Jj" uniqKey="Palop J">JJ Palop</name></author><author><name sortKey="Yan, F" uniqKey="Yan F">F Yan</name></author><author><name sortKey="Cheng, Ih" uniqKey="Cheng I">IH Cheng</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ittner, Lm" uniqKey="Ittner L">LM Ittner</name></author><author><name sortKey="Ke, Yd" uniqKey="Ke Y">YD Ke</name></author><author><name sortKey="Delerue, F" uniqKey="Delerue F">F Delerue</name></author><author><name sortKey="Bi, M" uniqKey="Bi M">M Bi</name></author><author><name sortKey="Gladbach, A" uniqKey="Gladbach A">A Gladbach</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ittner, Lm" uniqKey="Ittner L">LM Ittner</name></author><author><name sortKey="Gotz, J" uniqKey="Gotz J">J Gotz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nikolaev, A" uniqKey="Nikolaev A">A Nikolaev</name></author><author><name sortKey="Mclaughlin, T" uniqKey="Mclaughlin T">T McLaughlin</name></author><author><name sortKey="O Leary, Dd" uniqKey="O Leary D">DD O'Leary</name></author><author><name sortKey="Tessier Lavigne, M" uniqKey="Tessier Lavigne M">M Tessier-Lavigne</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="D Amelio, M" uniqKey="D Amelio M">M D'Amelio</name></author><author><name sortKey="Cavallucci, V" uniqKey="Cavallucci V">V Cavallucci</name></author><author><name sortKey="Middei, S" uniqKey="Middei S">S Middei</name></author><author><name sortKey="Marchetti, C" uniqKey="Marchetti C">C Marchetti</name></author><author><name sortKey="Pacioni, S" uniqKey="Pacioni S">S Pacioni</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Halliwell, B" uniqKey="Halliwell B">B Halliwell</name></author><author><name sortKey="Cross, Ce" uniqKey="Cross C">CE Cross</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Eckert, A" uniqKey="Eckert A">A Eckert</name></author><author><name sortKey="Schmitt, K" uniqKey="Schmitt K">K Schmitt</name></author><author><name sortKey="Gotz, J" uniqKey="Gotz J">J Gotz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tillement, L" uniqKey="Tillement L">L Tillement</name></author><author><name sortKey="Lecanu, L" uniqKey="Lecanu L">L Lecanu</name></author><author><name sortKey="Papadopoulos, V" uniqKey="Papadopoulos V">V Papadopoulos</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Eckert, A" uniqKey="Eckert A">A Eckert</name></author><author><name sortKey="Hauptmann, S" uniqKey="Hauptmann S">S Hauptmann</name></author><author><name sortKey="Scherping, I" uniqKey="Scherping I">I Scherping</name></author><author><name sortKey="Rhein, V" uniqKey="Rhein V">V Rhein</name></author><author><name sortKey="Muller Spahn, F" uniqKey="Muller Spahn F">F Muller-Spahn</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Caspersen, C" uniqKey="Caspersen C">C Caspersen</name></author><author><name sortKey="Wang, N" uniqKey="Wang N">N Wang</name></author><author><name sortKey="Yao, J" uniqKey="Yao J">J Yao</name></author><author><name sortKey="Sosunov, A" uniqKey="Sosunov A">A Sosunov</name></author><author><name sortKey="Chen, X" uniqKey="Chen X">X Chen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lustbader, Jw" uniqKey="Lustbader J">JW Lustbader</name></author><author><name sortKey="Cirilli, M" uniqKey="Cirilli M">M Cirilli</name></author><author><name sortKey="Lin, C" uniqKey="Lin C">C Lin</name></author><author><name sortKey="Xu, Hw" uniqKey="Xu H">HW Xu</name></author><author><name sortKey="Takuma, K" uniqKey="Takuma K">K Takuma</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Crouch, Pj" uniqKey="Crouch P">PJ Crouch</name></author><author><name sortKey="Blake, R" uniqKey="Blake R">R Blake</name></author><author><name sortKey="Duce, Ja" uniqKey="Duce J">JA Duce</name></author><author><name sortKey="Ciccotosto, Gd" uniqKey="Ciccotosto G">GD Ciccotosto</name></author><author><name sortKey="Li, Qx" uniqKey="Li Q">QX Li</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Keil, U" uniqKey="Keil U">U Keil</name></author><author><name sortKey="Bonert, A" uniqKey="Bonert A">A Bonert</name></author><author><name sortKey="Marques, Ca" uniqKey="Marques C">CA Marques</name></author><author><name sortKey="Scherping, I" uniqKey="Scherping I">I Scherping</name></author><author><name sortKey="Weyermann, J" uniqKey="Weyermann J">J Weyermann</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="David, Dc" uniqKey="David D">DC David</name></author><author><name sortKey="Hauptmann, S" uniqKey="Hauptmann S">S Hauptmann</name></author><author><name sortKey="Scherping, I" uniqKey="Scherping I">I Scherping</name></author><author><name sortKey="Schuessel, K" uniqKey="Schuessel K">K Schuessel</name></author><author><name sortKey="Keil, U" uniqKey="Keil U">U Keil</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Eckert, A" uniqKey="Eckert A">A Eckert</name></author><author><name sortKey="Hauptmann, S" uniqKey="Hauptmann S">S Hauptmann</name></author><author><name sortKey="Scherping, I" uniqKey="Scherping I">I Scherping</name></author><author><name sortKey="Meinhardt, J" uniqKey="Meinhardt J">J Meinhardt</name></author><author><name sortKey="Rhein, V" uniqKey="Rhein V">V Rhein</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rhein, V" uniqKey="Rhein V">V Rhein</name></author><author><name sortKey="Song, X" uniqKey="Song X">X Song</name></author><author><name sortKey="Wiesner, A" uniqKey="Wiesner A">A Wiesner</name></author><author><name sortKey="Ittner, Lm" uniqKey="Ittner L">LM Ittner</name></author><author><name sortKey="Baysang, G" uniqKey="Baysang G">G Baysang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yan, Sd" uniqKey="Yan S">SD Yan</name></author><author><name sortKey="Fu, J" uniqKey="Fu J">J Fu</name></author><author><name sortKey="Soto, C" uniqKey="Soto C">C Soto</name></author><author><name sortKey="Chen, X" uniqKey="Chen X">X Chen</name></author><author><name sortKey="Zhu, H" uniqKey="Zhu H">H Zhu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Takuma, K" uniqKey="Takuma K">K Takuma</name></author><author><name sortKey="Yao, J" uniqKey="Yao J">J Yao</name></author><author><name sortKey="Huang, J" uniqKey="Huang J">J Huang</name></author><author><name sortKey="Xu, H" uniqKey="Xu H">H Xu</name></author><author><name sortKey="Chen, X" uniqKey="Chen X">X Chen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yao, J" uniqKey="Yao J">J Yao</name></author><author><name sortKey="Taylor, M" uniqKey="Taylor M">M Taylor</name></author><author><name sortKey="Davey, F" uniqKey="Davey F">F Davey</name></author><author><name sortKey="Ren, Y" uniqKey="Ren Y">Y Ren</name></author><author><name sortKey="Aiton, J" uniqKey="Aiton J">J Aiton</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yao, J" uniqKey="Yao J">J Yao</name></author><author><name sortKey="Du, H" uniqKey="Du H">H Du</name></author><author><name sortKey="Yan, S" uniqKey="Yan S">S Yan</name></author><author><name sortKey="Fang, F" uniqKey="Fang F">F Fang</name></author><author><name sortKey="Wang, C" uniqKey="Wang C">C Wang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Moeller, G" uniqKey="Moeller G">G Moeller</name></author><author><name sortKey="Adamski, J" uniqKey="Adamski J">J Adamski</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="He, Xy" uniqKey="He X">XY He</name></author><author><name sortKey="Merz, G" uniqKey="Merz G">G Merz</name></author><author><name sortKey="Yang, Yz" uniqKey="Yang Y">YZ Yang</name></author><author><name sortKey="Mehta, P" uniqKey="Mehta P">P Mehta</name></author><author><name sortKey="Schulz, H" uniqKey="Schulz H">H Schulz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yang, Sy" uniqKey="Yang S">SY Yang</name></author><author><name sortKey="He, Xy" uniqKey="He X">XY He</name></author><author><name sortKey="Miller, D" uniqKey="Miller D">D Miller</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Henderson, Vw" uniqKey="Henderson V">VW Henderson</name></author><author><name sortKey="Brinton, Rd" uniqKey="Brinton R">RD Brinton</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="He, Xy" uniqKey="He X">XY He</name></author><author><name sortKey="Merz, G" uniqKey="Merz G">G Merz</name></author><author><name sortKey="Mehta, P" uniqKey="Mehta P">P Mehta</name></author><author><name sortKey="Schulz, H" uniqKey="Schulz H">H Schulz</name></author><author><name sortKey="Yang, Sy" uniqKey="Yang S">SY Yang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="He, Xy" uniqKey="He X">XY He</name></author><author><name sortKey="Merz, G" uniqKey="Merz G">G Merz</name></author><author><name sortKey="Yang, Yz" uniqKey="Yang Y">YZ Yang</name></author><author><name sortKey="Pullakart, R" uniqKey="Pullakart R">R Pullakart</name></author><author><name sortKey="Mehta, P" uniqKey="Mehta P">P Mehta</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ivell, R" uniqKey="Ivell R">R Ivell</name></author><author><name sortKey="Balvers, M" uniqKey="Balvers M">M Balvers</name></author><author><name sortKey="Anand, Rj" uniqKey="Anand R">RJ Anand</name></author><author><name sortKey="Paust, Hj" uniqKey="Paust H">HJ Paust</name></author><author><name sortKey="Mckinnell, C" uniqKey="Mckinnell C">C McKinnell</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yao, J" uniqKey="Yao J">J Yao</name></author><author><name sortKey="Irwin, R" uniqKey="Irwin R">R Irwin</name></author><author><name sortKey="Chen, S" uniqKey="Chen S">S Chen</name></author><author><name sortKey="Hamilton, R" uniqKey="Hamilton R">R Hamilton</name></author><author><name sortKey="Cadenas, E" uniqKey="Cadenas E">E Cadenas</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rauschenberger, K" uniqKey="Rauschenberger K">K Rauschenberger</name></author><author><name sortKey="Scholer, K" uniqKey="Scholer K">K Scholer</name></author><author><name sortKey="Sass, Jo" uniqKey="Sass J">JO Sass</name></author><author><name sortKey="Sauer, S" uniqKey="Sauer S">S Sauer</name></author><author><name sortKey="Djuric, Z" uniqKey="Djuric Z">Z Djuric</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Holzmann, J" uniqKey="Holzmann J">J Holzmann</name></author><author><name sortKey="Frank, P" uniqKey="Frank P">P Frank</name></author><author><name sortKey="Loffler, E" uniqKey="Loffler E">E Loffler</name></author><author><name sortKey="Bennett, Kl" uniqKey="Bennett K">KL Bennett</name></author><author><name sortKey="Gerner, C" uniqKey="Gerner C">C Gerner</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Holzmann, J" uniqKey="Holzmann J">J Holzmann</name></author><author><name sortKey="Rossmanith, W" uniqKey="Rossmanith W">W Rossmanith</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yan, Y" uniqKey="Yan Y">Y Yan</name></author><author><name sortKey="Liu, Y" uniqKey="Liu Y">Y Liu</name></author><author><name sortKey="Sorci, M" uniqKey="Sorci M">M Sorci</name></author><author><name sortKey="Belfort, G" uniqKey="Belfort G">G Belfort</name></author><author><name sortKey="Lustbader, Jw" uniqKey="Lustbader J">JW Lustbader</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Oppermann, Uc" uniqKey="Oppermann U">UC Oppermann</name></author><author><name sortKey="Salim, S" uniqKey="Salim S">S Salim</name></author><author><name sortKey="Tjernberg, Lo" uniqKey="Tjernberg L">LO Tjernberg</name></author><author><name sortKey="Terenius, L" uniqKey="Terenius L">L Terenius</name></author><author><name sortKey="Jornvall, H" uniqKey="Jornvall H">H Jornvall</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chen, X" uniqKey="Chen X">X Chen</name></author><author><name sortKey="Yan, Sd" uniqKey="Yan S">SD Yan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kissinger, Cr" uniqKey="Kissinger C">CR Kissinger</name></author><author><name sortKey="Rejto, Pa" uniqKey="Rejto P">PA Rejto</name></author><author><name sortKey="Pelletier, La" uniqKey="Pelletier L">LA Pelletier</name></author><author><name sortKey="Thomson, Ja" uniqKey="Thomson J">JA Thomson</name></author><author><name sortKey="Showalter, Re" uniqKey="Showalter R">RE Showalter</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ferrari, A" uniqKey="Ferrari A">A Ferrari</name></author><author><name sortKey="Hoerndli, F" uniqKey="Hoerndli F">F Hoerndli</name></author><author><name sortKey="Baechi, T" uniqKey="Baechi T">T Baechi</name></author><author><name sortKey="Nitsch, Rm" uniqKey="Nitsch R">RM Nitsch</name></author><author><name sortKey="Gotz, J" uniqKey="Gotz J">J Gotz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hoerndli, Fj" uniqKey="Hoerndli F">FJ Hoerndli</name></author><author><name sortKey="Toigo, M" uniqKey="Toigo M">M Toigo</name></author><author><name sortKey="Schild, A" uniqKey="Schild A">A Schild</name></author><author><name sortKey="Gotz, J" uniqKey="Gotz J">J Gotz</name></author><author><name sortKey="Day, Pj" uniqKey="Day P">PJ Day</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kenney, Am" uniqKey="Kenney A">AM Kenney</name></author><author><name sortKey="Kocsis, Jd" uniqKey="Kocsis J">JD Kocsis</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Budd, Sl" uniqKey="Budd S">SL Budd</name></author><author><name sortKey="Castilho, Rf" uniqKey="Castilho R">RF Castilho</name></author><author><name sortKey="Nicholls, Dg" uniqKey="Nicholls D">DG Nicholls</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Marques, At" uniqKey="Marques A">AT Marques</name></author><author><name sortKey="Fernandes, Pa" uniqKey="Fernandes P">PA Fernandes</name></author><author><name sortKey="Ramos, Mj" uniqKey="Ramos M">MJ Ramos</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Muirhead, Ke" uniqKey="Muirhead K">KE Muirhead</name></author><author><name sortKey="Froemming, M" uniqKey="Froemming M">M Froemming</name></author><author><name sortKey="Li, X" uniqKey="Li X">X Li</name></author><author><name sortKey="Musilek, K" uniqKey="Musilek K">K Musilek</name></author><author><name sortKey="Conway, Sj" uniqKey="Conway S">SJ Conway</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Borger, E" uniqKey="Borger E">E Borger</name></author><author><name sortKey="Aitken, L" uniqKey="Aitken L">L Aitken</name></author><author><name sortKey="Muirhead, Ke" uniqKey="Muirhead K">KE Muirhead</name></author><author><name sortKey="Allen, Ze" uniqKey="Allen Z">ZE Allen</name></author><author><name sortKey="Ainge, Ja" uniqKey="Ainge J">JA Ainge</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rhein, V" uniqKey="Rhein V">V Rhein</name></author><author><name sortKey="Baysang, G" uniqKey="Baysang G">G Baysang</name></author><author><name sortKey="Rao, S" uniqKey="Rao S">S Rao</name></author><author><name sortKey="Meier, F" uniqKey="Meier F">F Meier</name></author><author><name sortKey="Bonert, A" uniqKey="Bonert A">A Bonert</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Afanas Ev, I" uniqKey="Afanas Ev I">I Afanas'ev</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dumont, M" uniqKey="Dumont M">M Dumont</name></author><author><name sortKey="Beal, Mf" uniqKey="Beal M">MF Beal</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lim, Y A" uniqKey="Lim Y">Y-A Lim</name></author><author><name sortKey="Rhein, V" uniqKey="Rhein V">V Rhein</name></author><author><name sortKey="Baysang, G" uniqKey="Baysang G">G Baysang</name></author><author><name sortKey="Meier, F" uniqKey="Meier F">F Meier</name></author><author><name sortKey="Poljak, A" uniqKey="Poljak A">A Poljak</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Moreira, Pi" uniqKey="Moreira P">PI Moreira</name></author><author><name sortKey="Duarte, Ai" uniqKey="Duarte A">AI Duarte</name></author><author><name sortKey="Santos, Ms" uniqKey="Santos M">MS Santos</name></author><author><name sortKey="Rego, Ac" uniqKey="Rego A">AC Rego</name></author><author><name sortKey="Oliveira, Cr" uniqKey="Oliveira C">CR Oliveira</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Winton, Mj" uniqKey="Winton M">MJ Winton</name></author><author><name sortKey="Lee, Eb" uniqKey="Lee E">EB Lee</name></author><author><name sortKey="Sun, E" uniqKey="Sun E">E Sun</name></author><author><name sortKey="Wong, Mm" uniqKey="Wong M">MM Wong</name></author><author><name sortKey="Leight, S" uniqKey="Leight S">S Leight</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Garcia Segura, Lm" uniqKey="Garcia Segura L">LM Garcia-Segura</name></author><author><name sortKey="Azcoitia, I" uniqKey="Azcoitia I">I Azcoitia</name></author><author><name sortKey="Doncarlos, Ll" uniqKey="Doncarlos L">LL DonCarlos</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Powell, Aj" uniqKey="Powell A">AJ Powell</name></author><author><name sortKey="Read, Ja" uniqKey="Read J">JA Read</name></author><author><name sortKey="Banfield, Mj" uniqKey="Banfield M">MJ Banfield</name></author><author><name sortKey="Gunn Moore, F" uniqKey="Gunn Moore F">F Gunn-Moore</name></author><author><name sortKey="Yan, Sd" uniqKey="Yan S">SD Yan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="He, Xy" uniqKey="He X">XY He</name></author><author><name sortKey="Wen, Gy" uniqKey="Wen G">GY Wen</name></author><author><name sortKey="Merz, G" uniqKey="Merz G">G Merz</name></author><author><name sortKey="Lin, D" uniqKey="Lin D">D Lin</name></author><author><name sortKey="Yang, Yz" uniqKey="Yang Y">YZ Yang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Marques, At" uniqKey="Marques A">AT Marques</name></author><author><name sortKey="Antunes, A" uniqKey="Antunes A">A Antunes</name></author><author><name sortKey="Fernandes, Pa" uniqKey="Fernandes P">PA Fernandes</name></author><author><name sortKey="Ramos, Mj" uniqKey="Ramos M">MJ Ramos</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gotz, J" uniqKey="Gotz J">J Gotz</name></author><author><name sortKey="Ittner, Lm" uniqKey="Ittner L">LM Ittner</name></author><author><name sortKey="Lim, Ya" uniqKey="Lim Y">YA Lim</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gotz, J" uniqKey="Gotz J">J Gotz</name></author><author><name sortKey="Eckert, A" uniqKey="Eckert A">A Eckert</name></author><author><name sortKey="Matamales, M" uniqKey="Matamales M">M Matamales</name></author><author><name sortKey="Ittner, Lm" uniqKey="Ittner L">LM Ittner</name></author><author><name sortKey="Liu, X" uniqKey="Liu X">X Liu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Patti, Me" uniqKey="Patti M">ME Patti</name></author><author><name sortKey="Corvera, S" uniqKey="Corvera S">S Corvera</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lim, Ya" uniqKey="Lim Y">YA Lim</name></author><author><name sortKey="Ittner, Lm" uniqKey="Ittner L">LM Ittner</name></author><author><name sortKey="Lim, Yl" uniqKey="Lim Y">YL Lim</name></author><author><name sortKey="Gotz, J" uniqKey="Gotz J">J Gotz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bucciantini, M" uniqKey="Bucciantini M">M Bucciantini</name></author><author><name sortKey="Giannoni, E" uniqKey="Giannoni E">E Giannoni</name></author><author><name sortKey="Chiti, F" uniqKey="Chiti F">F Chiti</name></author><author><name sortKey="Baroni, F" uniqKey="Baroni F">F Baroni</name></author><author><name sortKey="Formigli, L" uniqKey="Formigli L">L Formigli</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bernas, T" uniqKey="Bernas T">T Bernas</name></author><author><name sortKey="Dobrucki, J" uniqKey="Dobrucki J">J Dobrucki</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lobner, D" uniqKey="Lobner D">D Lobner</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yao, J" uniqKey="Yao J">J Yao</name></author><author><name sortKey="Irwin, Rw" uniqKey="Irwin R">RW Irwin</name></author><author><name sortKey="Zhao, L" uniqKey="Zhao L">L Zhao</name></author><author><name sortKey="Nilsen, J" uniqKey="Nilsen J">J Nilsen</name></author><author><name sortKey="Hamilton, Rt" uniqKey="Hamilton R">RT Hamilton</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Seo, Js" uniqKey="Seo J">JS Seo</name></author><author><name sortKey="Lee, Kw" uniqKey="Lee K">KW Lee</name></author><author><name sortKey="Kim, Tk" uniqKey="Kim T">TK Kim</name></author><author><name sortKey="Baek, Is" uniqKey="Baek I">IS Baek</name></author><author><name sortKey="Im, Jy" uniqKey="Im J">JY Im</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yan, Sd" uniqKey="Yan S">SD Yan</name></author><author><name sortKey="Shi, Y" uniqKey="Shi Y">Y Shi</name></author><author><name sortKey="Zhu, A" uniqKey="Zhu A">A Zhu</name></author><author><name sortKey="Fu, J" uniqKey="Fu J">J Fu</name></author><author><name sortKey="Zhu, H" uniqKey="Zhu H">H Zhu</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22174920</article-id><article-id pub-id-type="pmc">3236223</article-id><article-id pub-id-type="publisher-id">PONE-D-11-14664</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0028887</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biology</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Enzymes</subject><subj-group><subject>Enzyme Kinetics</subject><subject>Enzyme Regulation</subject></subj-group></subj-group><subj-group><subject>Metabolism</subject><subject>Neurochemistry</subject><subject>Small Molecules</subject></subj-group></subj-group><subj-group><subject>Biotechnology</subject><subj-group><subject>Small Molecules</subject></subj-group></subj-group><subj-group><subject>Neuroscience</subject><subj-group><subject>Molecular Neuroscience</subject><subject>Neural Homeostasis</subject><subject>Neurobiology of Disease and Regeneration</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine</subject><subj-group><subject>Neurology</subject><subj-group><subject>Dementia</subject><subj-group><subject>Alzheimer Disease</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Inhibition of the Mitochondrial Enzyme ABAD Restores the Amyloid-β-Mediated Deregulation of Estradiol</article-title><alt-title alt-title-type="running-head">ABAD Inhibition Restores Amyloid-β's Toxic Effects</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lim</surname><given-names>Yun-An</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Grimm</surname><given-names>Amandine</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Giese</surname><given-names>Maria</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mensah-Nyagan</surname><given-names>Ayikoe Guy</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Villafranca</surname><given-names>J. Ernest</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ittner</surname><given-names>Lars M.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Eckert</surname><given-names>Anne</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author"><name><surname>Götz</surname><given-names>Jürgen</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Alzheimer's & Parkinson's Disease Laboratory, Brain & Mind Research Institute, University of Sydney, Camperdown, New South Wales, Australia</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Neurobiology Laboratory, Psychiatric University Clinics Basel, University of Basel, Basel, Switzerland</addr-line></aff><aff id="aff3"><label>3</label><addr-line>Equipe Steroïdes, Neuromodulateurs et Neuropathologies, Université de Strasbourg, Strasbourg, France</addr-line></aff><aff id="aff4"><label>4</label><addr-line>Villafranca Consulting, San Diego, California, United States of America</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>El Khoury</surname><given-names>Joseph</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"></xref></contrib></contrib-group><aff id="edit1">Massachusetts General Hospital and Harvard Medical School, United States of America</aff><author-notes><corresp id="cor1">* E-mail: <email>juergen.goetz@sydney.edu.au</email> (JG);<email>Anne.Eckert@upkbs.ch</email> (AE)</corresp><fn fn-type="con"><p>Conceived and designed the experiments: Y-AL AE JG. Performed the experiments: Y-AL AG MG. Analyzed the data: Y-AL AE AGM-N JEV LMI JG. Contributed reagents/materials/analysis tools: JEV. Wrote the paper: Y-AL JG.</p></fn></author-notes><pub-date pub-type="collection"><year>2011</year></pub-date><pub-date pub-type="epub"><day>12</day><month>12</month><year>2011</year></pub-date><volume>6</volume><issue>12</issue><elocation-id>e28887</elocation-id><history><date date-type="received"><day>28</day><month>7</month><year>2011</year></date><date date-type="accepted"><day>16</day><month>11</month><year>2011</year></date></history><permissions><copyright-statement>Lim et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement><copyright-year>2011</copyright-year></permissions><abstract><p>Alzheimer's disease (AD) is a conformational disease that is characterized by amyloid-β (Aβ) deposition in the brain. Aβ exerts its toxicity in part by receptor-mediated interactions that cause down-stream protein misfolding and aggregation, as well as mitochondrial dysfunction. Recent reports indicate that Aβ may also interact directly with intracellular proteins such as the mitochondrial enzyme ABAD (Aβ binding alcohol dehydrogenase) in executing its toxic effects. Mitochondrial dysfunction occurs early in AD, and Aβ's toxicity is in part mediated by inhibition of ABAD as shown previously with an ABAD decoy peptide. Here, we employed AG18051, a novel small ABAD-specific compound inhibitor, to investigate the role of ABAD in Aβ toxicity. Using SH-SY5Y neuroblastoma cells, we found that AG18051 partially blocked the Aβ-ABAD interaction in a pull-down assay while it also prevented the Aβ42-induced down-regulation of ABAD activity, as measured by levels of estradiol, a known hormone and product of ABAD activity. Furthermore, AG18051 is protective against Aβ42 toxicity, as measured by LDH release and MTT absorbance. Specifically, AG18051 reduced Aβ42-induced impairment of mitochondrial respiration and oxidative stress as shown by reduced ROS (reactive oxygen species) levels. Guided by our previous finding of shared aspects of the toxicity of Aβ and human amylin (HA), with the latter forming aggregates in Type 2 diabetes mellitus (T2DM) pancreas, we determined whether AG18051 would also confer protection from HA toxicity. We found that the inhibitor conferred only partial protection from HA toxicity indicating distinct pathomechanisms of the two amyloidogenic agents. Taken together, our results present the inhibition of ABAD by compounds such as AG18051 as a promising therapeutic strategy for the prevention and treatment of AD, and suggest levels of estradiol as a suitable read-out.</p></abstract><counts><page-count count="12"></page-count></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>In the Alzheimer's disease (AD) brain, amyloid-β (Aβ) has a central yet only partly understood role in the neurodegenerative process <xref ref-type="bibr" rid="pone.0028887-Gotz1">[1]</xref>. Apart from constituting the amyloid plaque as a classical hallmark lesion of AD, Aβ acts via a plethora of pathways to induce synaptic and neuronal degeneration <xref ref-type="bibr" rid="pone.0028887-Small1">[2]</xref>–<xref ref-type="bibr" rid="pone.0028887-Hoerndli1">[4]</xref>. Many studies reveal that in exerting its toxicity, Aβ binds to specific receptors and/or lipids at the neuronal cell membrane, and some studies even suggest a disruption of ion homeostasis by forming channels or pores <xref ref-type="bibr" rid="pone.0028887-Lin1">[5]</xref>, <xref ref-type="bibr" rid="pone.0028887-Cappai1">[6]</xref>. To better understand what the prerequisites are for Aβ toxicity, we and others used transgenic mouse models and found that Aβ mediates its toxicity in part through the NMDA receptor, with an essential role for the microtubule-associated protein tau <xref ref-type="bibr" rid="pone.0028887-Roberson1">[7]</xref>–<xref ref-type="bibr" rid="pone.0028887-Ittner2">[9]</xref>, that similar to Aβ, also forms insoluble aggregates in the AD brain. Over-activation of the NMDA receptor complex results in excessive nitric oxide (NO) levels, causing down-stream protein misfolding and aggregation, as well as mitochondrial dysfunction. The toxic signaling pathway further involves the release of mitochondrial cytochrome c and the activation of down-stream caspases as well as the formation of ROS (reactive oxygen species) <xref ref-type="bibr" rid="pone.0028887-Nikolaev1">[10]</xref>–<xref ref-type="bibr" rid="pone.0028887-Halliwell1">[12]</xref>, highlighting mitochondria as a prime down-stream target of Aβ <xref ref-type="bibr" rid="pone.0028887-Eckert1">[13]</xref>–<xref ref-type="bibr" rid="pone.0028887-Eckert2">[15]</xref>.</p><p>Interestingly, mitochondria represent not only an indirect target; instead, in several studies Aβ has been localized to <xref ref-type="bibr" rid="pone.0028887-Caspersen1">[16]</xref> and shown to act directly on mitochondria <xref ref-type="bibr" rid="pone.0028887-Lustbader1">[17]</xref>, <xref ref-type="bibr" rid="pone.0028887-Crouch1">[18]</xref> whose function it impairs <xref ref-type="bibr" rid="pone.0028887-Keil1">[19]</xref>–<xref ref-type="bibr" rid="pone.0028887-Rhein1">[22]</xref>. Among the mitochondrial proteins to which Aβ has been shown to bind is the enzyme amyloid-binding alcohol dehydrogenase (ABAD) <xref ref-type="bibr" rid="pone.0028887-Yan1">[23]</xref>, <xref ref-type="bibr" rid="pone.0028887-Takuma1">[24]</xref>. ABAD interacts with Aβ and is a major determinant of Aβ toxicity <xref ref-type="bibr" rid="pone.0028887-Lustbader1">[17]</xref>, <xref ref-type="bibr" rid="pone.0028887-Yao1">[25]</xref>, <xref ref-type="bibr" rid="pone.0028887-Yao2">[26]</xref>. Specifically, in mice doubly transgenic for ABAD and the Aβ-precursor APP, the toxic effects of Aβ are aggravated compared to what is found in APP single transgenic mice <xref ref-type="bibr" rid="pone.0028887-Lustbader1">[17]</xref>.</p><p>ABAD is the Type 10 member of a protein family, known as 17β-hydroxysteroid dehydrogenases (HSD17B) <xref ref-type="bibr" rid="pone.0028887-Moeller1">[27]</xref>. The enzyme is found in mitochondria, while the other known fourteen family members are confined to the endoplasmic reticulum (ER) suggesting that ABAD has a specialized function within mitochondria <xref ref-type="bibr" rid="pone.0028887-He1">[28]</xref>. ABAD converts estradiol to estrone <xref ref-type="bibr" rid="pone.0028887-Yang1">[29]</xref>, and its levels are critical as optimal estradiol levels are an important determinant of neuronal survival <xref ref-type="bibr" rid="pone.0028887-Yang1">[29]</xref>. In post-menopausal women, the estrogen replacement therapy has been shown to delay the onset of AD <xref ref-type="bibr" rid="pone.0028887-Henderson1">[30]</xref>. In the placenta and in ovaries, ABAD inactivates estradiol by oxidizing it to estrone <xref ref-type="bibr" rid="pone.0028887-He2">[31]</xref>, <xref ref-type="bibr" rid="pone.0028887-He3">[32]</xref>, and this may also occurs in testis <xref ref-type="bibr" rid="pone.0028887-Ivell1">[33]</xref>. Interestingly, ABAD levels themselves are sensitive to estradiol levels suggesting a feedback loop in the regulation of its activity <xref ref-type="bibr" rid="pone.0028887-Yao3">[34]</xref>.</p><p>The many reports of ABAD's enzymatic action on various substrates <italic>in vivo</italic> have been challenged, however, by strong evidence that a catalytically inactive mutant of ABAD as identified in a young boy had no ill effects on his health <xref ref-type="bibr" rid="pone.0028887-Rauschenberger1">[35]</xref>. In addition, ABAD was found to be one of only three proteins that comprise the fully functional mammalian mitochondrial RNAse P <xref ref-type="bibr" rid="pone.0028887-Holzmann1">[36]</xref>, a function that may not require enzymatic activity and that links ABAD directly to the production of mitochondrial electron transport chain proteins and reactive oxygen species (ROS) generation <xref ref-type="bibr" rid="pone.0028887-Holzmann2">[37]</xref>.</p><p>Binding of Aβ to ABAD induces a conformational change that is inhibited by NAD<sup>+</sup> (nicotinamide adenine dinucleotide), with binding of Aβ and NAD<sup>+</sup> being mutually exclusive <xref ref-type="bibr" rid="pone.0028887-Yan2">[38]</xref>. Aβ binding results in the loss of ABAD function and ultimately, neuronal apoptosis <xref ref-type="bibr" rid="pone.0028887-Oppermann1">[39]</xref>, <xref ref-type="bibr" rid="pone.0028887-Chen1">[40]</xref>. To directly determine whether Aβ-induced toxicity is mediated by ABAD inhibition and to establish estradiol levels as a suitable readout, we here employed the use of AG18051, a novel ABAD inhibitor <xref ref-type="bibr" rid="pone.0028887-Kissinger1">[41]</xref>.</p></sec><sec sec-type="materials|methods" id="s2"><title>Materials and Methods</title><sec id="s2a"><title>Cell culture and incubation with amyloid peptides</title><p>SH-SY5Y neuroblastoma cells (DSMZ, Braunschweig, Germany; DSMZ No. ACC 209) were grown in Dulbecco's Modified Eagle Medium: F-12 (DMEM: F-12) supplemented with 2 mM L-glutamine, 1% penicillin/streptomycin and 10% fetal bovine serum (FBS) (GIBCO, Basel, Switzerland) <xref ref-type="bibr" rid="pone.0028887-Ferrari1">[42]</xref>, <xref ref-type="bibr" rid="pone.0028887-Hoerndli2">[43]</xref>. Aβ42, human amylin (HA), biotinylated Aβ42 and biotinylated HA were purchased from Bachem (Germany) (H-1368, H-7905, H-5642 and 3004028, respectively). The negative control, biotin, was purchased from Sigma (B4639). Biotinylated and unmodified Aβ42 were dissolved in DMSO to make stocks of 5 mM and stored at −80°C until use. Biotinylated and unmodified HA were dissolved in 0.01 M acetic acid (AA) to make stocks of 5 mM and also stored at −80°C until use. Biotin was dissolved in DMSO to make stocks of 5 mM and kept at −80°C until use. Aging of the peptides was induced by shaking at 1000 rpm for 4 days at 37°C. 0.5 µM Aβ42 or human amylin (HA) was used for all experiments in this study, while the treatment duration was always 5 days. Pre-treatment experiments were performed by incubating SH-SY5Y cells with 0.05 µM AG18051 for 24 hours, washing 3 times with warm PBS, and then treating the cells with 0.5 µM Aβ42 or HA for 5 days. Co-treatment experiments were done by incubating SH-SY5Y cells for 5 days with 0.05 µM AG18051 and 0.5 µM Aβ42 or HA, respectively.</p></sec><sec id="s2b"><title>LDH and MTT assays</title><p>LDH and MTT assays were chosen to provide indications for cell viability after treatments. Assays were obtained from Roche and were performed according to the manufacturer's protocols. Briefly, cells were exposed to the various treatments, after which the medium was retrieved for LDH analysis, while the remaining cells were washed 3 times with sterile PBS and the MTT assay performed with the cells.</p></sec><sec id="s2c"><title>Pull-down assay</title><p>SH-SY5Y cells were grown to 70% confluency and treated with vehicle, biotinylated Aβ42, biotinylated HA, or biotin, respectively, at a final concentration of 0.5 µM for 5 days. In addition, 0.5 µM biotin and 0.5 µM biotinylated Aβ42, respectively, was co-incubated with 0.05 µM AG18051 for 5 days. After 5 days, cells were once washed with pre-warmed PBS and immediately scraped with 500 µL ice-cold IP buffer (10 mM Tris, 0.1 M NaCl, 1 mM EDTA), supplemented with the Complete EDTA-free protease inhibitor cocktail (1∶25) (Roche, Basel, Switzerland), and spun at 14 000× g for 10 minutes at 4°C. 20 µl of magnetic Dynabeads MyOne™ Streptavidin T1 (Invitrogen) were added to each tube and tubes were rotated for 30 minutes at room temperature. Beads were subsequently washed 3 times with 1× PBS, followed by boiling in loading buffer containing β-mercaptoethanol at 95°C for 5 minutes at 1000 rpm to release bound peptides. Samples were then briefly spun down at room temperature and supernatants loaded onto 12% glycine gels for electrophoresis and Western blotting.</p></sec><sec id="s2d"><title>Quantification of estradiol as a functional read-out of ABAD activity</title><p>After treatment with amyloid peptides and controls, the cell culture medium was collected and cells were resuspended in cell lysis buffer consisting of 150 mM Tris HCl, 150 mM NaCl, 1% NP-40, 0.1% SDS, 2 mM EDTA and Complete protease inhibitor (1∶50) (Roche Diagnostics). The estradiol assay was performed according to the manufacturer's guidelines (Estradiol EIA Kit, Cayman). In brief, the plate was loaded with samples, along with the estradiol tracer and the specific antiserum to estradiol and incubated for one hour at room temperature. After five washing steps, Ellman's Reagent was added and the plate developed for 60 minutes with gentle shaking at room temperature. The calculated estradiol concentration was normalized to the total protein content of the samples.</p></sec><sec id="s2e"><title>Mitochondrial respiration in vital cells</title><p>After treatment with amyloid peptides and controls, mitochondrial oxygen consumption was measured at 37°C using an Oroboros Oxygraph-2k system. Five million cells were added to 2 ml of a mitochondrial respiration medium containing 0.5 mM EGTA, 3 mM MgCl<sub>2</sub>, 60 mM K-lactobionate, 20 mM taurine, 10 mM KH<sub>2</sub>P0<sub>4</sub>, 20 mM HEPES, 110 mM sucrose and 1 g/l BSA (pH 7.1). To measure the state 4 respiration of complex I, 5 mM pyruvate and 2 mM malate were added and cells permeabilised with 15 µg/ml digitonin. Afterwards, 2 mM ADP was added to measure state 3 respiration. The integrity of the mitochondrial membrane was checked by the addition of 10 µM cytochrome c. After determining coupled respiration, 0.4 µM FCCP (Carbonyl cyanide p-(trifluoro-methoxy) phenyl-hydrazone) was added and respiration was measured in the absence of a proton gradient. To inhibit complex I activity, 0.5 µM rotenone was added.</p></sec><sec id="s2f"><title>Determining ROS levels</title><p>Levels of ROS were measured using different fluorescent probes that allow detection at different cellular sites. The non-fluorescent probe 2′,7′-dichlorodihydrofluorescein diacetate (H2DCF-DA) was used to measure cytosolic ROS, most notably hydrogen peroxide <xref ref-type="bibr" rid="pone.0028887-Kenney1">[44]</xref>. To determine levels of superoxide anion radicals, DHE was used, which is oxidized to the fluorescent ethidium cation by O2<sup>.−</sup> <xref ref-type="bibr" rid="pone.0028887-Rhein1">[22]</xref>. For detection of mitochondria-associated ROS we used the probe dihydrorhodamine (DHR), which localizes to mitochondria and when oxidized by ROS, particularly peroxinitrite, fluoresces to the positively charged rhodamine 123 derivate. Treated cells (Aβ42, HA, and vehicle) were loaded with 10 µM H2DCF-DA, 10 µM DHR or 10 µM DHE, respectively, for 15 min. After washing twice with Hank's balanced salt (HBS) solution, the formation of fluorescent products was measured by detecting the emitted fluorescent units per 5×10<sup>5</sup> cells using the Fluoraskan Ascent FL multiplate reader (Labsystems, Helsinki, Finland) (i) at 485 nm (excitation)/538 nm (emission) for both dichlorofluorescein (DCF) generated from H2DCF-DA via oxidation, and DHR, and (ii) at 530 nm (excitation)/590 nm (emission) for DHE, as previously described <xref ref-type="bibr" rid="pone.0028887-Budd1">[45]</xref>.</p></sec></sec><sec id="s3"><title>Results</title><sec id="s3a"><title>Aβ42 binds to and down-regulates ABAD activity, different from human amylin</title><p>Aβ exerts its toxicity in part by impairing ABAD <xref ref-type="bibr" rid="pone.0028887-Lustbader1">[17]</xref>, an enzyme known to convert estrone to estradiol. To determine the toxicity of the major fibrillogenic form of Aβ and the role ABAD has in this process, we incubated human SH-SY5Y neuroblastoma cells for 5 days with Aβ42, followed by measuring estradiol levels in the cell lysate. We found that its levels were significantly decreased after Aβ42 exposure (p<0.0001) (<xref ref-type="fig" rid="pone-0028887-g001">Fig. 1A</xref>). To determine if the deregulation of ABAD activity is a common phenomenon shared by Aβ with other amyloidogenic proteins, we treated the cells also with human amylin (HA), a protein twice the size of Aβ and known to form aggregates in another disease with protein aggregation, Type 2 diabetes mellitus (T2DM). However, different from Aβ42, HA did not cause reductions in estradiol levels (p<0.0001) (<xref ref-type="fig" rid="pone-0028887-g001">Fig. 1A</xref>).</p><fig id="pone-0028887-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0028887.g001</object-id><label>Figure 1</label><caption><title>Aβ42 binds to and impairs ABAD activity, while HA (human amylin) does not.</title><p>(A) Treatment of SH-SY5Y human neuroblastoma cells with Aβ42 causes decreased levels of estradiol, indicative of an impairment of ABAD activity, while HA does not. Results are means ± SE, (n = 5 to 6 per group), <bold>**</bold>, <italic>P</italic><0.01 (B) Pull-down of ABAD from SH-SY5Y cells shows that different from HA, Aβ42 can bind to ABAD <italic>in vitro</italic>. (C) Structure of the ABAD inhibitor, AG18051 (adapted from Kissinger et al., JMB 2004).</p></caption><graphic xlink:href="pone.0028887.g001"></graphic></fig><p>Data obtained by x-ray crystallography of Aβ42-ABAD complexes indicate that it may be the direct association of Aβ42 and ABAD that inhibits ABAD activity, as an association of Aβ with ABAD prevents it from binding to its physiological substrate, NAD<sup>+</sup> <xref ref-type="bibr" rid="pone.0028887-Lustbader1">[17]</xref>. Since HA, different from Aβ42, did not down-regulate ABAD activity as measured by estradiol levels, and as it is known that Aβ42 is capable of inhibiting ABAD activity by direct interaction <xref ref-type="bibr" rid="pone.0028887-Yan2">[38]</xref>, we sought to determine whether HA, similar to Aβ, would interact with ABAD. Therefore, SH-SY5Y cells were incubated with 0.5 µM biotinylated Aβ42 (BAβ), biotinylated HA (BHA), biotin or vehicle for 5 days. We found by pull-down that while biotinylated Aβ42 was bound to ABAD, biotinylated HA, along with the negative control, was not (<xref ref-type="fig" rid="pone-0028887-g001">Fig. 1B</xref>). Together with the estradiol activity assay, this suggests that the reductions in estradiol levels caused by Aβ42 may be mediated by a direct interaction of Aβ with ABAD.</p></sec><sec id="s3b"><title>The ABAD inhibitor AG18051 causes reduced estradiol levels</title><p>To better understand the effect of Aβ on estradiol levels we used AG18051, a small molecule inhibitor of ABAD with high affinity <xref ref-type="bibr" rid="pone.0028887-Kissinger1">[41]</xref>, <xref ref-type="bibr" rid="pone.0028887-Marques1">[46]</xref> (<xref ref-type="fig" rid="pone-0028887-g001">Fig. 1C</xref>). AG18051 exerts its inhibitory effect by occupying the substrate-binding site of ABAD, which results in the formation of a covalent adduct with the NAD<sup>+</sup> cofactor. As the interaction of ABAD with NAD<sup>+</sup> is necessary for its activity, disrupting ABAD/NAD<sup>+</sup> complex formation obliterates ABAD activity, resulting in decreased estradiol levels. We first determined the toxicity profile of AG18051 in our SH-SY5Y cell culture system. Concentrations of AG18051 up to 0.1 µM were not overtly toxic and therefore, concentrations within the 0.05–0.1 µM range were chosen for subsequent studies (<xref ref-type="fig" rid="pone-0028887-g002">Fig. 2A</xref>). The toxicity at higher concentrations argues for a proper dosing. The concentration range applied by us is consistent with the IC<sub>50</sub> determined for AG18051 in a previous study <xref ref-type="bibr" rid="pone.0028887-Muirhead1">[47]</xref>, <xref ref-type="bibr" rid="pone.0028887-Borger1">[48]</xref>. With increasing concentrations of the inhibitor, as expected, estradiol levels were reduced (<xref ref-type="fig" rid="pone-0028887-g002">Fig. 2B</xref>). At 0.05 µM however, there was a slight, but non-significant increase in estradiol levels suggesting compensatory mechanisms.</p><fig id="pone-0028887-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0028887.g002</object-id><label>Figure 2</label><caption><title>Effects of the ABAD inhibitor AG18051 on cell viability and estradiol levels.</title><p>(A) LDH assay of SH-SY5Y human neuroblastoma cells incubated with increasing concentrations of AG18051 (normalized to 1 for control) shows that the ABAD inhibitor is not toxic at concentrations of 0.1 µM and below. (B) Treatment of SH-SY5Y cells with increasing concentrations of AG18051 causes reduced levels of estradiol. <bold>*</bold>, <italic>P</italic><0.05.</p></caption><graphic xlink:href="pone.0028887.g002"></graphic></fig></sec><sec id="s3c"><title>AG18051 prevents Aβ42-induced reductions in estradiol levels</title><p>To determine whether AG18051 has an effect on the Aβ42-induced reduction of estradiol levels (<xref ref-type="fig" rid="pone-0028887-g001">Fig. 1A</xref>) and whether the putative neuroprotective effect is via a ‘priming effect’ of the cells, we both pre- and co-incubated SH-SY5Y cells with Aβ42 and 0.05–0.1 µM AG18051 as outlined in the scheme (<xref ref-type="fig" rid="pone-0028887-g003">Fig. 3A</xref>). For both treatment conditions, we found that this maintained estradiol levels in the lysate, compared to a significant reduction in the Aβ42-only treatment (<xref ref-type="fig" rid="pone-0028887-g003">Fig. 3B,C</xref>). This suggests that AG18051 is neuroprotective, and that it may exert its neuroprotective effect either by priming cells to become resistant to the effects of Aβ42, or via a direct inhibition of the Aβ42-ABAD interaction as previously suggested <xref ref-type="bibr" rid="pone.0028887-Kissinger1">[41]</xref>.</p><fig id="pone-0028887-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0028887.g003</object-id><label>Figure 3</label><caption><title>The Aβ-mediated decrease in estradiol levels is prevented by AG18051.</title><p>(A) Scheme of pre- and co-incubation treatment. (B) Pre-treatment of cells with AG18051 for 24 hours prior to adding Aβ42 maintains estradiol levels compared to the vehicle control, (C) as does co-treatment. **, <italic>P</italic><0.01.</p></caption><graphic xlink:href="pone.0028887.g003"></graphic></fig></sec><sec id="s3d"><title>AG18051 partially prevents ABAD-Aβ42 interaction</title><p>To determine whether AG18051 treatment reverses the Aβ42-induced toxicity because AG18051 directly blocks the physical interaction between Aβ42 and ABAD, SH-SY5Y cells were treated with 0.5 µM of biotinylated Aβ42 (BAβ) in the presence of 0.05 µM AG18051. We found that co-incubation of AG18051 significantly decreased the amount of ABAD pulled down by biotinylated Aβ42 (BAβ) (<xref ref-type="fig" rid="pone-0028887-g004"><bold>Fig. 4</bold></xref>). This suggests that AG18051 may prevent Aβ42 toxicity by directly inhibiting the association of Aβ42 with ABAD. In addition, this also suggests that AG18051 may exert its neuroprotective effects via additional pathways other than a direct inhibition of the Aβ42-ABAD interaction.</p><fig id="pone-0028887-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0028887.g004</object-id><label>Figure 4</label><caption><title>Pull-down of ABAD from SH-SY5Y cells shows that different from HA, Aβ42 can bind to ABAD <italic>in vitro</italic>.</title><p>The presence of AG18051 significantly decreases the amount of ABAD pulled down by biotinylated Aβ42 (BAβ). *, p<0.05.</p></caption><graphic xlink:href="pone.0028887.g004"></graphic></fig></sec><sec id="s3e"><title>Aβ42-mediated reduction in cell viability prevented by ABAD inhibitor AG18051</title><p>Having determined 0.05–0.1 µM as a suitable concentration range for AG18051, we tested its putative neuroprotective effect in Aβ42 toxicity. SH-SY5Y cells were incubated with 0.5 µM Aβ42 with or without AG18051, and toxicity was determined as increased levels of LDH compared to vehicle control. Co-incubation of Aβ42 with either 0.05 or 0.1 µM AG18051, respectively, resulted in a significant decrease in LDH levels back to control levels (<xref ref-type="fig" rid="pone-0028887-g005">Fig. 5A</xref>). This indicates that inhibiting ABAD activity protects from Aβ toxicity.</p><fig id="pone-0028887-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0028887.g005</object-id><label>Figure 5</label><caption><title>The ABAD inhibitor AG18051 prevents the toxicity and metabolic impairment caused by Aβ.</title><p>(A) Co-incubation of AG18051 and Aβ42 maintains the Aβ42-induced change in LDH levels at baseline levels. (B) The metabolic impairment as determined with the MTT assay is also prevented by co-incubation of Aβ42 with AG18051. (C) Pre-incubation of the cells with AG18051 for 24 hours prior to adding Aβ42 is similarly protective to Aβ's toxicity as measured with the MTT assay. <bold>*</bold>, <italic>P</italic><0.05; <bold>**</bold>, <italic>P</italic><0.01; <bold>***</bold>, <italic>P</italic><0.001.</p></caption><graphic xlink:href="pone.0028887.g005"></graphic></fig><p>We next investigated the effect of Aβ on metabolic functions and found that besides significantly increasing LDH levels, 0.5 µM Aβ42 also caused a significant decrease in MTT absorbance, suggesting impaired metabolic functions caused by this amyloidogenic peptide (<xref ref-type="fig" rid="pone-0028887-g005">Fig. 5B</xref>). Co-incubation of Aβ42 with either 0.05 or 0.1 µM AG18051, respectively, resulted in a smaller decrease of MTT absorbance (<xref ref-type="fig" rid="pone-0028887-g005">Fig. 5B,C</xref>). Since MTT measurements are an indicator of mitochondrial health, the results suggest that Aβ42 induces cell toxicity, as reflected by LDH levels, at least in parts via impaired mitochondrial functions, with inhibition of the mitochondrial enzyme ABAD providing partial protection.</p></sec><sec id="s3f"><title>AG18051 restored Aβ42-induced deficits on oxidative phosphorylation (OXPHOS) capacity</title><p>To investigate the protective effect of AG18051 against Aβ42 toxicity at the mitochondrial level, we used a high-resolution respiratory protocol that we have established previously <xref ref-type="bibr" rid="pone.0028887-Rhein2">[49]</xref>. Specifically, physiological substrate combinations were used to investigate mitochondrial function in SH-SY5Y cells (<xref ref-type="fig" rid="pone-0028887-g006">Fig. 6</xref>). We compared OXPHOS, i.e. the entire electron transport system (ETS) that is composed of the four mitochondrial enzymes (complex I–IV) and the F<sub>1</sub>F<sub>0</sub>ATP synthase, in cells treated with either vehicle, Aβ42, AG18051, as well as in cells that were pre-treated with AG18051 followed by exposure to Aβ42 (see scheme, <xref ref-type="fig" rid="pone-0028887-g003">Fig. 3A</xref>). We used the NADH generating substrates pyruvate and malate to determine state 4 respiration (<xref ref-type="fig" rid="pone-0028887-g006">Fig. 6</xref>). State 3 respiration measures the capacity of mitochondria to metabolize oxygen and the selected substrate in the presence of a defined amount of ADP, which is a substrate for the ATP synthase (complex V). State 4 respiration represents a “basal-coupled” rate of respiratory chain activity and reflects activities of respiratory chain complexes and proton leakage across the inner mitochondrial membrane. We observed significantly reduced state 3 and state 4 respirations in Aβ42-treated cells (<xref ref-type="fig" rid="pone-0028887-g006">Fig. 6</xref>). After uncoupling with FCCP, the respiratory rate increased in the absence of a proton gradient, which indicates the maximum capacity of electron transport chain. This maximum OXPHOS capacity was again significantly impaired in Aβ42-treated (<xref ref-type="fig" rid="pone-0028887-g006">Fig. 6</xref>).</p><fig id="pone-0028887-g006" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0028887.g006</object-id><label>Figure 6</label><caption><title>High-resolution respirometry revealed a reduction of oxygen consumption in Aβ42-treated cells that was restored after pre-treatment with AG18051.</title><p>O<sub>2</sub> flux and consumption by vital cells was measured after addition of different agents: pyruvate/glutamate, ADP, FCCP, rotenone. Two-way ANOVA revealed a significant difference between the cellular respiration of the cells treated either with vehicle, Aβ42 or AG18051 alone, or AG18051 plus Aβ42 (p<0.0001) (see scheme <xref ref-type="fig" rid="pone-0028887-g003">Fig. 3A</xref>). The respiratory rates of mitochondria were significantly reduced in Aβ42-treated cells compared to control (vehicle treated) cells and cells pre-treated with AG18051 (24 h) before exposure to Aβ42. Values represent the means ± S.E. from n = 3–5 independent measurements. Post-hoc Bonferroni's Multiple Comparison Test analysis for single experimental respiratory conditions: *, p<0.05; **, p<0.01; ***, p<0.001.</p></caption><graphic xlink:href="pone.0028887.g006"></graphic></fig><p>Of note, AG18051 was able to significantly ameliorate the Aβ42-induced global failure of mitochondrial respiration, but by itself had no effect <italic>per se</italic> on oxygen consumption attaining levels comparable to vehicle treatment (<xref ref-type="fig" rid="pone-0028887-g006">Fig. 6</xref>).</p></sec><sec id="s3g"><title>AG18051 prevents the increase in ROS levels caused by Aβ42</title><p>Increased ROS levels have been implicated in AD <xref ref-type="bibr" rid="pone.0028887-Afanasev1">[50]</xref>, <xref ref-type="bibr" rid="pone.0028887-Dumont1">[51]</xref>. We had previously found that treatment of SH-SY5Y cells with Aβ42 caused significantly increased ROS (reactive oxygen species) levels, reflecting mitochondrial dysfunction and cell toxicity <xref ref-type="bibr" rid="pone.0028887-Lim1">[52]</xref>. As pre-incubation with AG18051 was capable of preventing the toxicity induced by Aβ42, we pre-treated SH-SY5Y cells with AG18051 and exposed them then to Aβ42. Interestingly, cells pre-treated with 0.05–0.1 µM AG18051 were effectively protected from any Aβ42-induced ROS production, attaining levels comparable to vehicle treatment (<xref ref-type="fig" rid="pone-0028887-g007">Fig. 7</xref>). This suggests that AG18051 may prevent cell toxicity induced by Aβ42 in part by preventing the generation of ROS. In addition, the results also suggest that ABAD dysfunction may be upstream of ROS production since AG18051 can prevent ROS generation. Alternatively, AG18051 may trigger high estradiol levels, thereby counteracting ROS.</p><fig id="pone-0028887-g007" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0028887.g007</object-id><label>Figure 7</label><caption><title>AG18051 pre-treatment prevents ROS generation induced by Aβ.</title><p>Aβ causes reduced cellular (DCF) as well as mitochondrial ROS (DHR), e.g. reduced mitochondrial superoxide anion radicals (DHE). Levels are restored to vehicle upon pre-treatment with AG18051, irrespective of whether the SH-SY5Y cells have been incubated with Aβ or HA. <bold>*</bold>, <italic>P</italic><0.05; <bold>***</bold>, <italic>P</italic><0.001.</p></caption><graphic xlink:href="pone.0028887.g007"></graphic></fig></sec><sec id="s3h"><title>AG18051 only partially protects against reductions in cell viability and estradiol levels in SH-SY5Y cells when deregulated by human amylin (HA)</title><p>Previously, we had found that Aβ42 and HA share toxicity pathways via deregulation of mitochondrial proteins <xref ref-type="bibr" rid="pone.0028887-Lim1">[52]</xref>. However, as shown above, Aβ42 binds to and down-regulates ABAD activity, while HA fails to do so (<xref ref-type="fig" rid="pone-0028887-g001">Fig. 1</xref>). We nonetheless sought to determine whether AG18051 would have an effect in the toxicity assays used above to measure Aβ toxicity. We found that HA induced an increase in LDH levels revealing its toxicity (<xref ref-type="fig" rid="pone-0028887-g008">Fig. 8A</xref>), and a corresponding decrease in MTT absorbance revealing its effect on metabolic functions (<xref ref-type="fig" rid="pone-0028887-g008">Fig. 8B</xref>). Co-incubation of AG18051 with HA significantly prevented the increase in LDH levels when compared with HA alone, but did not fully maintain LDH to the levels of vehicle treatment indicating only a partial protection from HA-induced toxicity (<xref ref-type="fig" rid="pone-0028887-g008">Fig. 8A</xref>). Co-incubation of AG18051 with HA did not have any significant impact on MTT levels (<xref ref-type="fig" rid="pone-0028887-g008">Fig. 8B</xref>).</p><fig id="pone-0028887-g008" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0028887.g008</object-id><label>Figure 8</label><caption><title>The ABAD inhibitor AG18051 partially prevents the toxicity of HA, but not its metabolic impairment.</title><p>(A) Co-incubation of HA with AG18051 partially maintains levels of LDH release in SH-SY5Y cells suggesting that the toxicity of HA is partially mediated by ABAD. (B) Treatment with 0.5 µM HA significantly decreases metabolic activity as shown with the MTT assay, which is not prevented with co-incubation with AG18051. <bold>*</bold>, <italic>P</italic><0.05; <bold>**</bold>, <italic>P</italic><0.01.</p></caption><graphic xlink:href="pone.0028887.g008"></graphic></fig></sec><sec id="s3i"><title>AG18051 prevents the increase in ROS levels caused by Aβ42 and HA</title><p>Increased ROS levels have not only been implicated in AD but also T2DM <xref ref-type="bibr" rid="pone.0028887-Afanasev1">[50]</xref>, <xref ref-type="bibr" rid="pone.0028887-Dumont1">[51]</xref>. We had previously found that ROS levels in SH-SY5Y cells are significantly increased upon exposure to either Aβ42 or HA <xref ref-type="bibr" rid="pone.0028887-Lim1">[52]</xref>. To determine if the limited protective effect seen by AG18051 on HA-induced toxicity may be due to an inhibition of ROS generation, we pre-incubated SH-SY5Y cells with AG18051 and then exposed them to HA. Similar to Aβ42 (<xref ref-type="fig" rid="pone-0028887-g007">Fig. 7</xref>), pre-treatment with 0.05 µM AG18051 completely prevented ROS generation by 0.5 µM HA (<xref ref-type="fig" rid="pone-0028887-g009">Fig. 9</xref>). Taken together with the ROS data obtained for Aβ42 (<xref ref-type="fig" rid="pone-0028887-g007">Fig. 7</xref>), this suggests that AG18051 may be neuroprotective by preventing ROS generation induced by either Aβ42 or HA.</p><fig id="pone-0028887-g009" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0028887.g009</object-id><label>Figure 9</label><caption><title>AG18051 pre-treatment prevents ROS generation also induced by HA.</title><p>As for Aβ, HA causes reduced cellular (A) as well as mitochondrial ROS (B), e.g. reduced mitochondrial superoxide anion radicals (C). Levels are restored to vehicle upon pre-treatment with AG18051. <bold>*</bold>, <italic>P</italic><0.05; <bold>***</bold>, <italic>P</italic><0.001.</p></caption><graphic xlink:href="pone.0028887.g009"></graphic></fig></sec></sec><sec id="s4"><title>Discussion</title><p>Mitochondrial dysfunction has been recognized as a prominent, early event in AD, but the underlying mechanisms are only partly understood <xref ref-type="bibr" rid="pone.0028887-Moreira1">[53]</xref>. As a mediator of Aβ toxicity in AD, a role has been proposed for the mitochondrial protein ABAD, with evidence for a direct interaction of Aβ and ABAD <xref ref-type="bibr" rid="pone.0028887-Lustbader1">[17]</xref>. Whether in the AD brain, intracellular Aβ - either in mitochondria or in the cytoplasm - is present at sufficiently high quantities to have a decisive role in disease is a matter to debate that has been revived by the recent analysis of Aβ plaque-forming 3xTg-AD using a panel of Aβ- and APP-specific antibodies <xref ref-type="bibr" rid="pone.0028887-Winton1">[54]</xref>. Our current study however adds to the body of data revealing a role for ABAD in mediating Aβ, irrespective of its mode of interaction.</p><p>By using the novel compound inhibitor of ABAD, AG18051 <xref ref-type="bibr" rid="pone.0028887-Kissinger1">[41]</xref>, we revealed that Aβ-mediated toxicity, metabolic impairment and reductions in estradiol levels could be abrogated. However different from Aβ, the inhibitor only partially restored the toxicity of HA, that shares with Aβ its amyloidogenic properties, and it had no effect at all on the impaired metabolic activities or the reduced estradiol levels caused by HA. The compound though abolished both the Aβ42- and HA-induced increases in ROS levels. These effects may or may not require a direct interaction of Aβ and ABAD. Provided that Aβ enters mitochondria and binds ABAD, it is believed to gain access to the mitochondrial matrix via intracellular trafficking. Our pull-down experiments using a biotinylated preparation of Aβ reveal that this peptide binds to ABAD in a lysate, while in contrast, HA does not.</p><p>One of the established functions of ABAD is to convert in an equilibrium reaction estrone to estradiol, a known anti-oxidant in neuronal survival <xref ref-type="bibr" rid="pone.0028887-He2">[31]</xref>–<xref ref-type="bibr" rid="pone.0028887-Ivell1">[33]</xref>, <xref ref-type="bibr" rid="pone.0028887-GarciaSegura1">[55]</xref>. Additional substrates are known for ABAD, such as the mitochondrial 2-methyl-3-hydroxybutyryl-CoA <xref ref-type="bibr" rid="pone.0028887-Chen1">[40]</xref>, <xref ref-type="bibr" rid="pone.0028887-Powell1">[56]</xref>.</p><p>ABAD is up-regulated in AD brain areas affected by Aβ pathology such as the cortex and hippocampus, as well as in Aβ-producing mouse models <xref ref-type="bibr" rid="pone.0028887-Lustbader1">[17]</xref>, <xref ref-type="bibr" rid="pone.0028887-Yan1">[23]</xref>, <xref ref-type="bibr" rid="pone.0028887-Yao2">[26]</xref>, <xref ref-type="bibr" rid="pone.0028887-He4">[57]</xref>. In neuroblastoma cells, the cytotoxic effects of Aβ are enhanced by ABAD over-expression, and blocked with anti-ABAD antibodies <xref ref-type="bibr" rid="pone.0028887-Marques2">[58]</xref>. Moreover, synthetic Aβ fragments have been shown to bind and inhibit ABAD <italic>in vitro</italic> <xref ref-type="bibr" rid="pone.0028887-Oppermann1">[39]</xref>. As cells expressing catalytically inactive mutants of ABAD failed to show an enhanced sensitivity to Aβ, it has been suggested that it is the enzymatic activity that is required for mediating Aβ toxicity <xref ref-type="bibr" rid="pone.0028887-Yan2">[38]</xref>. <italic>In vivo</italic>, ABAD over-expression potentiates the toxic effects of Aβ, and obliteration of Aβ-ABAD complexes restores cell viability and memory deficits in transgenic mice <xref ref-type="bibr" rid="pone.0028887-Lustbader1">[17]</xref>, <xref ref-type="bibr" rid="pone.0028887-Yao2">[26]</xref>. This inhibition was achieved using a truncated version of ABAD as a decoy peptide (ABAD<sup>DP</sup>) <xref ref-type="bibr" rid="pone.0028887-Lustbader1">[17]</xref>, <xref ref-type="bibr" rid="pone.0028887-Yao2">[26]</xref>. The authors of the study concluded that segregating ABAD from Aβ protects both mitochondria and neurons from Aβ toxicity by restoring ABAD's physiological functions.</p><p>Rather than employing a decoy peptide, we decided to use the small compound, AG18051, a novel ABAD inhibitor to investigate its putative protective effects. We performed co- and pre-incubation experiments to determine whether the restoration of estradiol levels by AG18051 is due to a direct inhibition of the Aβ42-ABAD interaction, or an indirect mechanism. By determining estradiol levels as a functional read-out of ABAD activity, we found that exposure to Aβ42 significantly decreased estradiol levels (<xref ref-type="fig" rid="pone-0028887-g003">Fig. 3B, C</xref>). We have been using SH-SY5Y cells, a well-established neuroblastoma cell line <xref ref-type="bibr" rid="pone.0028887-Hoerndli2">[43]</xref>, to determine the effects of AG18051 on ABAD. We found that pre-treatment of SH-SY5Y cells with AG18051 before Aβ42 exposure (<xref ref-type="fig" rid="pone-0028887-g005">Fig. 5C</xref>) was sufficient to prevent the decrease in cell viability. This suggests that AG18051 is capable of blocking Aβ42 toxicity, possibly in part by directly binding to ABAD and preventing the Aβ42 toxicity mediated by ABAD.</p><p>To determine whether these changes are due to ABAD specifically, we performed co-incubation treatments of a novel ABAD inhibitor, AG18051, with Aβ42. We found that AG18051 effectively obliterated the toxic effects of Aβ42 as demonstrated by the restoration of LDH release and MTT absorbance to levels indistinguishable from the vehicle control. Furthermore, AG18051 restored estradiol levels upon down-regulation by Aβ42. This effect is seen both in the cell lysate and the medium (data not shown), suggesting that Aβ42 exerts its toxicity by interfering with intracellular levels of estradiol while also decreasing its secretion into the extracellular environment. Our data indicate that Aβ42-induced toxicity is mediated by ABAD in part via the deregulation of estradiol, which may contribute to cell toxicity.</p><p>To determine whether the change in estradiol levels is due to a direct blockage of Aβ42 by ABAD, we performed a pull-down using biotinylated Aβ42 in the presence of AG18051 (<xref ref-type="fig" rid="pone-0028887-g004">Fig. 4</xref>). We found that AG18051 significantly decreased ABAD binding to biotinylated Aβ42, suggesting that AG18051 may be neuroprotective, in part by disrupting the physical interaction of ABAD with Aβ42. However, as binding was not completely abolished, our results suggest that AG18051 may also act indirectly to prevent cell toxicity. This is supported by the fact that AG18051 is capable of preventing ROS production by HA (<xref ref-type="fig" rid="pone-0028887-g009">Fig. 9</xref>) even though HA does not seem to bind to ABAD (<xref ref-type="fig" rid="pone-0028887-g001">Fig. 1B</xref>).</p><p>To unravel the effects of Aβ42 and the involvement of ABAD on the mitochondrial respiratory capacity, we performed whole cell recording of total cellular respiration in SH-SY5Y cells (<xref ref-type="fig" rid="pone-0028887-g006">Fig. 6</xref>). Consistent with previous findings investigating the effect of a stable APP over-expression in SH-SY5Y cells gaining a chronic overproduction of Aβ within the low nanomolar range <xref ref-type="bibr" rid="pone.0028887-Rhein2">[49]</xref>, we observed a comparable impairment of oxygen consumption rates in cells treated with Aβ42 species for 5 days. Of note, we present for the first time clear evidence that pre-treatment with AG18051 prevented SH-SY5Y cells from a decline in metabolic energy pathways induced by Aβ42. The capacity of mitochondria to re-phosphorylate ADP in state 3 is dependent on the degree of coupling. Thus, pre-treatment with AG18051 prevented the ETC (electronic transport chain) from Aβ42 toxicity and rescued the coupling state of mitochondria. Importantly, the comparison of the mitochondrial energetic capacity in cells treated with vehicle or AG18051 revealed a similar bioenergetic homeostasis indicating that the inhibitor, by itself, had no significant effect on respiration. These results corroborate our findings demonstrating an AG18051-induced prevention of ROS formation caused by Aβ42, which in turn impairs mitochondrial function.</p><p>That a defective or insufficient mitochondrial function might play a potentially pathogenic role in another epidemic disease, Type 2 diabetes mellitus (T2DM), has emerged in recent years <xref ref-type="bibr" rid="pone.0028887-Gotz2">[59]</xref>, <xref ref-type="bibr" rid="pone.0028887-Gotz3">[60]</xref>. The association of diabetes with obesity and inactivity indicates an important, and potentially pathogenic, link between fuel and energy homeostasis and the emergence of metabolic disease. Given the central role for mitochondria in fuel utilization and energy production, mitochondrial dysfunction at the cellular level can impact whole-body metabolic homeostasis <xref ref-type="bibr" rid="pone.0028887-Patti1">[61]</xref>. T2DM is characterized by HA deposition in the pancreas, and AD by Aβ deposition in the brain <xref ref-type="bibr" rid="pone.0028887-Gotz2">[59]</xref>. Aβ and HA share a common β-sheet secondary structure, a strong determinant in toxicity <xref ref-type="bibr" rid="pone.0028887-Lim2">[62]</xref>, <xref ref-type="bibr" rid="pone.0028887-Bucciantini1">[63]</xref>. Supporting this notion we have shown previously that Aβ and HA share a mitochondrial toxicity profile <xref ref-type="bibr" rid="pone.0028887-Lim1">[52]</xref>. In the present study we found that HA caused toxicity and impaired metabolic functions. When we co-incubated HA with AG18051 using the same conditions as for Aβ42, AG18051 significantly decreased levels of LDH compared to just HA alone, suggesting that HA toxicity is in part mediated by ABAD (<xref ref-type="fig" rid="pone-0028887-g008">Fig. 8A</xref>). Interestingly, co-incubation of AG18051 with HA did not significantly change levels of MTT absorbance, an established assay of mitochondrial function (<xref ref-type="fig" rid="pone-0028887-g008">Fig. 8B</xref>) <xref ref-type="bibr" rid="pone.0028887-Bernas1">[64]</xref>. We have previously shown that to mitochondria, at equimolar concentration, HA is more toxic than Aβ42 <xref ref-type="bibr" rid="pone.0028887-Lim1">[52]</xref>. This suggests that a higher concentration of AG18051 may be required to restore the HA-induced mitochondrial toxicity. Interestingly, while the MTT assay is a reliable test for metabolic impairment, it does not always precisely reflect neuroprotective effects, suggesting that the LDH assay is more accurate in determining neurotoxicity <xref ref-type="bibr" rid="pone.0028887-Lobner1">[65]</xref>. It is therefore possible that the neuroprotective effects of AG18051 against HA treatment differs from that of Aβ42. By extrapolation, this also means that HA and Aβ42 may exert a differential toxicity on ABAD. This is a possibility, as exposure to HA did not alter estradiol levels, different from Aβ42 (<xref ref-type="fig" rid="pone-0028887-g001">Fig. 1A</xref>).</p><p>Pre-treatment of SH-SY5Y cells with AG18051 prevented both the cellular and mitochondrial ROS formation induced by Aβ42 and HA suggesting that ABAD is involved in their mechanism of toxicity. We have shown previously that increased ROS generation and reduced mitochondrial complex IV activity was the common mechanism of toxicity of HA and Aβ42 <xref ref-type="bibr" rid="pone.0028887-Lim1">[52]</xref>. This is in agreement, in the case of Aβ, with other reports showing that Aβ results in ROS generation and reduction of complex IV in AD mouse models and that there is a direct involvement of ABAD in these processes <xref ref-type="bibr" rid="pone.0028887-Lustbader1">[17]</xref>, <xref ref-type="bibr" rid="pone.0028887-Yao4">[66]</xref>, <xref ref-type="bibr" rid="pone.0028887-Seo1">[67]</xref>. Now it appears that HA ROS generation is also mediated by ABAD. However, while AG18051 may be protecting against most of the toxic effects of Aβ42, it does so only partially for HA. This indicates that HA may have additional toxicity pathways unrelated to ROS generation or ABAD.</p><p>The mechanism of protection by AG18051 is probably through its inactivation of ABAD's catalytic activity. Inactive mutants of ABAD do not enhance the toxicity of Aβ that is observed when wildtype ABAD is over-expressed, despite the fact that Aβ still binds to the mutant ABAD with the same affinity as wild-type <xref ref-type="bibr" rid="pone.0028887-Yan3">[68]</xref>. It has also been reported that siRNA-ABAD and the subsequent reduction of ABAD expression prevents the toxic effects of Aβ in SH-SY5Y cells induced to over-express ABAD by corticosterone and Aβ <xref ref-type="bibr" rid="pone.0028887-Seo1">[67]</xref>. But why would the catalytic activity of ABAD be harmful when Aβ is bound to it? In view of the participation of ABAD in mitochondrial RNAse P, which is responsible for the centrally important processing of the mitochondrial ETC mRNA <xref ref-type="bibr" rid="pone.0028887-Holzmann2">[37]</xref>, one possibility is that ABAD's primary function is as an RNAse P and that Aβ and HA induce a toxic gain of function related to its catalytic activity compromising its RNAse P function. This would result in aberrant processing of the ETC mRNA, a dysfunctional ETC and ROS generation. Aβ may do this directly by binding to ABAD and, while there is no evidence that HA directly interacts with ABAD, our study shows that ABAD is nevertheless key to the toxicity of HA.</p><p>In conclusion, we extend previous findings on the role of mitochondria, and in particular the mitochondrial enzyme ABAD, in mediating Aβ42 toxicity. We established a neuroprotective effect of AG18051, a novel ABAD-specific inhibitor, and showed that it promotes cell survival in part by preventing the generation of ROS and stabilizing estradiol levels. Our findings extend previous studies suggesting ABAD activity as a suitable biomarker for impaired brain functions. We further present AG18051 and related compounds for consideration in therapeutic strategies targeting AD.</p></sec></body><back><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>This research was supported by grants to JG from the Australian Research Council (ARC), the NHMRC (National Health and Medical Research Council), and the Judith Jane Mason & Harold Stannett Williams Memorial Foundation, to LMI from the NHMRC and ARC, and to AE from the Swiss National Science Foundation (SNF #310000-108223). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group><ref-list><title>References</title><ref id="pone.0028887-Gotz1"><label>1</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Gotz</surname><given-names>J</given-names></name><name><surname>Ittner</surname><given-names>LM</given-names></name><name><surname>Schonrock</surname><given-names>N</given-names></name><name><surname>Cappai</surname><given-names>R</given-names></name></person-group> <year>2008</year> <article-title>An update on the toxicity of Abeta in Alzheimer's disease.</article-title> <source>Neuropsychiatr Dis Treat</source> <volume>4</volume> <fpage>1033</fpage> <lpage>1042</lpage> <pub-id pub-id-type="pmid">19337449</pub-id></element-citation></ref><ref id="pone.0028887-Small1"><label>2</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Small</surname><given-names>DH</given-names></name><name><surname>Mok</surname><given-names>SS</given-names></name><name><surname>Bornstein</surname><given-names>JC</given-names></name></person-group> <year>2001</year> <article-title>OPINION Alzheimer's disease and Abeta toxicity: from top to bottom.</article-title> <source>Nat Rev Neurosci</source> <volume>2</volume> <fpage>595</fpage> <lpage>598</lpage> <pub-id pub-id-type="pmid">11484003</pub-id></element-citation></ref><ref id="pone.0028887-David1"><label>3</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>David</surname><given-names>DC</given-names></name><name><surname>Ittner</surname><given-names>LM</given-names></name><name><surname>Gehrig</surname><given-names>P</given-names></name><name><surname>Nergenau</surname><given-names>D</given-names></name><name><surname>Shepherd</surname><given-names>C</given-names></name><etal></etal></person-group> <year>2006</year> <article-title>β-Amyloid treatment of two complementary P301L tau-expressing Alzheimer's disease models reveals similar deregulated cellular processes.</article-title> <source>Proteomics</source> <volume>6</volume> <fpage>6566</fpage> <lpage>6577</lpage> <pub-id pub-id-type="pmid">17111439</pub-id></element-citation></ref><ref id="pone.0028887-Hoerndli1"><label>4</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Hoerndli</surname><given-names>F</given-names></name><name><surname>David</surname><given-names>D</given-names></name><name><surname>Gotz</surname><given-names>J</given-names></name></person-group> <year>2005</year> <article-title>Functional genomics meets neurodegenerative disorders. Part II: Application and data integration.</article-title> <source>Prog Neurobiol</source> <volume>76</volume> <fpage>169</fpage> <lpage>188</lpage> <pub-id pub-id-type="pmid">16169146</pub-id></element-citation></ref><ref id="pone.0028887-Lin1"><label>5</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Lin</surname><given-names>H</given-names></name><name><surname>Bhatia</surname><given-names>R</given-names></name><name><surname>Lal</surname><given-names>R</given-names></name></person-group> <year>2001</year> <article-title>Amyloid beta protein forms ion channels: implications for Alzheimer's disease pathophysiology.</article-title> <source>Faseb J</source> <volume>15</volume> <fpage>2433</fpage> <lpage>2444</lpage> <pub-id pub-id-type="pmid">11689468</pub-id></element-citation></ref><ref id="pone.0028887-Cappai1"><label>6</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Cappai</surname><given-names>R</given-names></name><name><surname>Barnham</surname><given-names>KJ</given-names></name></person-group> <year>2008</year> <article-title>Delineating the mechanism of Alzheimer's disease A beta peptide neurotoxicity.</article-title> <source>Neurochem Res</source> <volume>33</volume> <fpage>526</fpage> <lpage>532</lpage> <pub-id pub-id-type="pmid">17762917</pub-id></element-citation></ref><ref id="pone.0028887-Roberson1"><label>7</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Roberson</surname><given-names>ED</given-names></name><name><surname>Scearce-Levie</surname><given-names>K</given-names></name><name><surname>Palop</surname><given-names>JJ</given-names></name><name><surname>Yan</surname><given-names>F</given-names></name><name><surname>Cheng</surname><given-names>IH</given-names></name><etal></etal></person-group> <year>2007</year> <article-title>Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model.</article-title> <source>Science</source> <volume>316</volume> <fpage>750</fpage> <lpage>754</lpage> <pub-id pub-id-type="pmid">17478722</pub-id></element-citation></ref><ref id="pone.0028887-Ittner1"><label>8</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Ittner</surname><given-names>LM</given-names></name><name><surname>Ke</surname><given-names>YD</given-names></name><name><surname>Delerue</surname><given-names>F</given-names></name><name><surname>Bi</surname><given-names>M</given-names></name><name><surname>Gladbach</surname><given-names>A</given-names></name><etal></etal></person-group> <year>2010</year> <article-title>Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models.</article-title> <source>Cell</source> <volume>142</volume> <fpage>387</fpage> <lpage>397</lpage> <pub-id pub-id-type="pmid">20655099</pub-id></element-citation></ref><ref id="pone.0028887-Ittner2"><label>9</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Ittner</surname><given-names>LM</given-names></name><name><surname>Gotz</surname><given-names>J</given-names></name></person-group> <year>2011</year> <article-title>Amyloid-beta and tau - a toxic pas de deux in Alzheimer's disease.</article-title> <source>Nat Rev Neurosci</source> <volume>12</volume> <fpage>65</fpage> <lpage>72</lpage> <pub-id pub-id-type="pmid">21193853</pub-id></element-citation></ref><ref id="pone.0028887-Nikolaev1"><label>10</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Nikolaev</surname><given-names>A</given-names></name><name><surname>McLaughlin</surname><given-names>T</given-names></name><name><surname>O'Leary</surname><given-names>DD</given-names></name><name><surname>Tessier-Lavigne</surname><given-names>M</given-names></name></person-group> <year>2009</year> <article-title>APP binds DR6 to trigger axon pruning and neuron death via distinct caspases.</article-title> <source>Nature</source> <volume>457</volume> <fpage>981</fpage> <lpage>989</lpage> <pub-id pub-id-type="pmid">19225519</pub-id></element-citation></ref><ref id="pone.0028887-DAmelio1"><label>11</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>D'Amelio</surname><given-names>M</given-names></name><name><surname>Cavallucci</surname><given-names>V</given-names></name><name><surname>Middei</surname><given-names>S</given-names></name><name><surname>Marchetti</surname><given-names>C</given-names></name><name><surname>Pacioni</surname><given-names>S</given-names></name><etal></etal></person-group> <year>2011</year> <article-title>Caspase-3 triggers early synaptic dysfunction in a mouse model of Alzheimer's disease.</article-title> <source>Nat Neurosci</source> <volume>14</volume> <fpage>69</fpage> <lpage>76</lpage> <pub-id pub-id-type="pmid">21151119</pub-id></element-citation></ref><ref id="pone.0028887-Halliwell1"><label>12</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Halliwell</surname><given-names>B</given-names></name><name><surname>Cross</surname><given-names>CE</given-names></name></person-group> <year>1994</year> <article-title>Oxygen-derived species: their relation to human disease and environmental stress.</article-title> <source>Environ Health Perspect</source> <volume>102</volume> <issue>Suppl 10</issue> <fpage>5</fpage> <lpage>12</lpage> <pub-id pub-id-type="pmid">7705305</pub-id></element-citation></ref><ref id="pone.0028887-Eckert1"><label>13</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Eckert</surname><given-names>A</given-names></name><name><surname>Schmitt</surname><given-names>K</given-names></name><name><surname>Gotz</surname><given-names>J</given-names></name></person-group> <year>2011</year> <article-title>Mitochondrial dysfunction - the beginning of the end in Alzheimer's disease? Separate and synergistic modes of tau and amyloid-beta toxicity.</article-title> <source>Alzheimers Res Ther</source> <volume>3</volume> <fpage>15</fpage> <pub-id pub-id-type="pmid">21545753</pub-id></element-citation></ref><ref id="pone.0028887-Tillement1"><label>14</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Tillement</surname><given-names>L</given-names></name><name><surname>Lecanu</surname><given-names>L</given-names></name><name><surname>Papadopoulos</surname><given-names>V</given-names></name></person-group> <year>2011</year> <article-title>Further Evidence on Mitochondrial Targeting of beta-Amyloid and Specificity of beta-Amyloid-Induced Mitotoxicity in Neurons.</article-title> <source>Neurodegener Dis</source> </element-citation></ref><ref id="pone.0028887-Eckert2"><label>15</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Eckert</surname><given-names>A</given-names></name><name><surname>Hauptmann</surname><given-names>S</given-names></name><name><surname>Scherping</surname><given-names>I</given-names></name><name><surname>Rhein</surname><given-names>V</given-names></name><name><surname>Muller-Spahn</surname><given-names>F</given-names></name><etal></etal></person-group> <year>2008</year> <article-title>Soluble beta-amyloid leads to mitochondrial defects in amyloid precursor protein and tau transgenic mice.</article-title> <source>Neurodegener Dis</source> <volume>5</volume> <fpage>157</fpage> <lpage>159</lpage> <pub-id pub-id-type="pmid">18322377</pub-id></element-citation></ref><ref id="pone.0028887-Caspersen1"><label>16</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Caspersen</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Yao</surname><given-names>J</given-names></name><name><surname>Sosunov</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><etal></etal></person-group> <year>2005</year> <article-title>Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease.</article-title> <source>Faseb J</source> <volume>19</volume> <fpage>2040</fpage> <lpage>2041</lpage> <pub-id pub-id-type="pmid">16210396</pub-id></element-citation></ref><ref id="pone.0028887-Lustbader1"><label>17</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Lustbader</surname><given-names>JW</given-names></name><name><surname>Cirilli</surname><given-names>M</given-names></name><name><surname>Lin</surname><given-names>C</given-names></name><name><surname>Xu</surname><given-names>HW</given-names></name><name><surname>Takuma</surname><given-names>K</given-names></name><etal></etal></person-group> <year>2004</year> <article-title>ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease.</article-title> <source>Science</source> <volume>304</volume> <fpage>448</fpage> <lpage>452</lpage> <pub-id pub-id-type="pmid">15087549</pub-id></element-citation></ref><ref id="pone.0028887-Crouch1"><label>18</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Crouch</surname><given-names>PJ</given-names></name><name><surname>Blake</surname><given-names>R</given-names></name><name><surname>Duce</surname><given-names>JA</given-names></name><name><surname>Ciccotosto</surname><given-names>GD</given-names></name><name><surname>Li</surname><given-names>QX</given-names></name><etal></etal></person-group> <year>2005</year> <article-title>Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta1-42.</article-title> <source>J Neurosci</source> <volume>25</volume> <fpage>672</fpage> <lpage>679</lpage> <pub-id pub-id-type="pmid">15659604</pub-id></element-citation></ref><ref id="pone.0028887-Keil1"><label>19</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Keil</surname><given-names>U</given-names></name><name><surname>Bonert</surname><given-names>A</given-names></name><name><surname>Marques</surname><given-names>CA</given-names></name><name><surname>Scherping</surname><given-names>I</given-names></name><name><surname>Weyermann</surname><given-names>J</given-names></name><etal></etal></person-group> <year>2004</year> <article-title>Amyloid beta-induced changes in nitric oxide production and mitochondrial activity lead to apoptosis.</article-title> <source>J Biol Chem</source> <volume>279</volume> <fpage>50310</fpage> <lpage>50320</lpage> <pub-id pub-id-type="pmid">15371443</pub-id></element-citation></ref><ref id="pone.0028887-David2"><label>20</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>David</surname><given-names>DC</given-names></name><name><surname>Hauptmann</surname><given-names>S</given-names></name><name><surname>Scherping</surname><given-names>I</given-names></name><name><surname>Schuessel</surname><given-names>K</given-names></name><name><surname>Keil</surname><given-names>U</given-names></name><etal></etal></person-group> <year>2005</year> <article-title>Proteomic and functional analysis reveal a mitochondrial dysfunction in P301L tau transgenic mice.</article-title> <source>J Biol Chem</source> <volume>280</volume> <fpage>23802</fpage> <lpage>23814</lpage> <pub-id pub-id-type="pmid">15831501</pub-id></element-citation></ref><ref id="pone.0028887-Eckert3"><label>21</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Eckert</surname><given-names>A</given-names></name><name><surname>Hauptmann</surname><given-names>S</given-names></name><name><surname>Scherping</surname><given-names>I</given-names></name><name><surname>Meinhardt</surname><given-names>J</given-names></name><name><surname>Rhein</surname><given-names>V</given-names></name><etal></etal></person-group> <year>2008</year> <article-title>Oligomeric and fibrillar species of β-amyloid (Aβ42) both impair mitochondrial function in P301L tau transgenic mice.</article-title> <source>J Mol Med</source> <volume>86</volume> <fpage>1255</fpage> <lpage>1267</lpage> <pub-id pub-id-type="pmid">18709343</pub-id></element-citation></ref><ref id="pone.0028887-Rhein1"><label>22</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Rhein</surname><given-names>V</given-names></name><name><surname>Song</surname><given-names>X</given-names></name><name><surname>Wiesner</surname><given-names>A</given-names></name><name><surname>Ittner</surname><given-names>LM</given-names></name><name><surname>Baysang</surname><given-names>G</given-names></name><etal></etal></person-group> <year>2009</year> <article-title>Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice.</article-title> <source>Proc Natl Acad Sci U S A</source> <volume>106</volume> <fpage>20057</fpage> <lpage>20062</lpage> <pub-id pub-id-type="pmid">19897719</pub-id></element-citation></ref><ref id="pone.0028887-Yan1"><label>23</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Yan</surname><given-names>SD</given-names></name><name><surname>Fu</surname><given-names>J</given-names></name><name><surname>Soto</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><etal></etal></person-group> <year>1997</year> <article-title>An intracellular protein that binds amyloid-beta peptide and mediates neurotoxicity in Alzheimer's disease.</article-title> <source>Nature</source> <volume>389</volume> <fpage>689</fpage> <lpage>695</lpage> <pub-id pub-id-type="pmid">9338779</pub-id></element-citation></ref><ref id="pone.0028887-Takuma1"><label>24</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Takuma</surname><given-names>K</given-names></name><name><surname>Yao</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><etal></etal></person-group> <year>2005</year> <article-title>ABAD enhances Abeta-induced cell stress via mitochondrial dysfunction.</article-title> <source>Faseb J</source> <volume>19</volume> <fpage>597</fpage> <lpage>598</lpage> <pub-id pub-id-type="pmid">15665036</pub-id></element-citation></ref><ref id="pone.0028887-Yao1"><label>25</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Yao</surname><given-names>J</given-names></name><name><surname>Taylor</surname><given-names>M</given-names></name><name><surname>Davey</surname><given-names>F</given-names></name><name><surname>Ren</surname><given-names>Y</given-names></name><name><surname>Aiton</surname><given-names>J</given-names></name><etal></etal></person-group> <year>2007</year> <article-title>Interaction of amyloid binding alcohol dehydrogenase/Abeta mediates up-regulation of peroxiredoxin II in the brains of Alzheimer's disease patients and a transgenic Alzheimer's disease mouse model.</article-title> <source>Mol Cell Neurosci</source> <volume>35</volume> <fpage>377</fpage> <lpage>382</lpage> <pub-id pub-id-type="pmid">17490890</pub-id></element-citation></ref><ref id="pone.0028887-Yao2"><label>26</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Yao</surname><given-names>J</given-names></name><name><surname>Du</surname><given-names>H</given-names></name><name><surname>Yan</surname><given-names>S</given-names></name><name><surname>Fang</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><etal></etal></person-group> <year>2011</year> <article-title>Inhibition of amyloid-beta (Abeta) peptide-binding alcohol dehydrogenase-Abeta interaction reduces Abeta accumulation and improves mitochondrial function in a mouse model of Alzheimer's disease.</article-title> <source>J Neurosci</source> <volume>31</volume> <fpage>2313</fpage> <lpage>2320</lpage> <pub-id pub-id-type="pmid">21307267</pub-id></element-citation></ref><ref id="pone.0028887-Moeller1"><label>27</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Moeller</surname><given-names>G</given-names></name><name><surname>Adamski</surname><given-names>J</given-names></name></person-group> <year>2006</year> <article-title>Multifunctionality of human 17beta-hydroxysteroid dehydrogenases.</article-title> <source>Mol Cell Endocrinol</source> <volume>248</volume> <fpage>47</fpage> <lpage>55</lpage> <pub-id pub-id-type="pmid">16413960</pub-id></element-citation></ref><ref id="pone.0028887-He1"><label>28</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>He</surname><given-names>XY</given-names></name><name><surname>Merz</surname><given-names>G</given-names></name><name><surname>Yang</surname><given-names>YZ</given-names></name><name><surname>Mehta</surname><given-names>P</given-names></name><name><surname>Schulz</surname><given-names>H</given-names></name><etal></etal></person-group> <year>2001</year> <article-title>Characterization and localization of human type10 17beta-hydroxysteroid dehydrogenase.</article-title> <source>Eur J Biochem</source> <volume>268</volume> <fpage>4899</fpage> <lpage>4907</lpage> <pub-id pub-id-type="pmid">11559359</pub-id></element-citation></ref><ref id="pone.0028887-Yang1"><label>29</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Yang</surname><given-names>SY</given-names></name><name><surname>He</surname><given-names>XY</given-names></name><name><surname>Miller</surname><given-names>D</given-names></name></person-group> <year>2007</year> <article-title>HSD17B10: a gene involved in cognitive function through metabolism of isoleucine and neuroactive steroids.</article-title> <source>Mol Genet Metab</source> <volume>92</volume> <fpage>36</fpage> <lpage>42</lpage> <pub-id pub-id-type="pmid">17618155</pub-id></element-citation></ref><ref id="pone.0028887-Henderson1"><label>30</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Henderson</surname><given-names>VW</given-names></name><name><surname>Brinton</surname><given-names>RD</given-names></name></person-group> <year>2010</year> <article-title>Menopause and mitochondria: windows into estrogen effects on Alzheimer's disease risk and therapy.</article-title> <source>Prog Brain Res</source> <volume>182</volume> <fpage>77</fpage> <lpage>96</lpage> <pub-id pub-id-type="pmid">20541661</pub-id></element-citation></ref><ref id="pone.0028887-He2"><label>31</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>He</surname><given-names>XY</given-names></name><name><surname>Merz</surname><given-names>G</given-names></name><name><surname>Mehta</surname><given-names>P</given-names></name><name><surname>Schulz</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>SY</given-names></name></person-group> <year>1999</year> <article-title>Human brain short chain L-3-hydroxyacyl coenzyme A dehydrogenase is a single-domain multifunctional enzyme. Characterization of a novel 17beta-hydroxysteroid dehydrogenase.</article-title> <source>J Biol Chem</source> <volume>274</volume> <fpage>15014</fpage> <lpage>15019</lpage> <pub-id pub-id-type="pmid">10329704</pub-id></element-citation></ref><ref id="pone.0028887-He3"><label>32</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>He</surname><given-names>XY</given-names></name><name><surname>Merz</surname><given-names>G</given-names></name><name><surname>Yang</surname><given-names>YZ</given-names></name><name><surname>Pullakart</surname><given-names>R</given-names></name><name><surname>Mehta</surname><given-names>P</given-names></name><etal></etal></person-group> <year>2000</year> <article-title>Function of human brain short chain L-3-hydroxyacyl coenzyme A dehydrogenase in androgen metabolism.</article-title> <source>Biochim Biophys Acta</source> <volume>1484</volume> <fpage>267</fpage> <lpage>277</lpage> <pub-id pub-id-type="pmid">10760475</pub-id></element-citation></ref><ref id="pone.0028887-Ivell1"><label>33</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Ivell</surname><given-names>R</given-names></name><name><surname>Balvers</surname><given-names>M</given-names></name><name><surname>Anand</surname><given-names>RJ</given-names></name><name><surname>Paust</surname><given-names>HJ</given-names></name><name><surname>McKinnell</surname><given-names>C</given-names></name><etal></etal></person-group> <year>2003</year> <article-title>Differentiation-dependent expression of 17beta-hydroxysteroid dehydrogenase, type 10, in the rodent testis: effect of aging in Leydig cells.</article-title> <source>Endocrinology</source> <volume>144</volume> <fpage>3130</fpage> <lpage>3137</lpage> <pub-id pub-id-type="pmid">12810569</pub-id></element-citation></ref><ref id="pone.0028887-Yao3"><label>34</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Yao</surname><given-names>J</given-names></name><name><surname>Irwin</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Hamilton</surname><given-names>R</given-names></name><name><surname>Cadenas</surname><given-names>E</given-names></name><etal></etal></person-group> <year>2011</year> <article-title>Ovarian hormone loss induces bioenergetic deficits and mitochondrial beta-amyloid.</article-title> <source>Neurobiol Aging</source> </element-citation></ref><ref id="pone.0028887-Rauschenberger1"><label>35</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Rauschenberger</surname><given-names>K</given-names></name><name><surname>Scholer</surname><given-names>K</given-names></name><name><surname>Sass</surname><given-names>JO</given-names></name><name><surname>Sauer</surname><given-names>S</given-names></name><name><surname>Djuric</surname><given-names>Z</given-names></name><etal></etal></person-group> <year>2010</year> <article-title>A non-enzymatic function of 17beta-hydroxysteroid dehydrogenase type 10 is required for mitochondrial integrity and cell survival.</article-title> <source>EMBO Mol Med</source> <volume>2</volume> <fpage>51</fpage> <lpage>62</lpage> <pub-id pub-id-type="pmid">20077426</pub-id></element-citation></ref><ref id="pone.0028887-Holzmann1"><label>36</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Holzmann</surname><given-names>J</given-names></name><name><surname>Frank</surname><given-names>P</given-names></name><name><surname>Loffler</surname><given-names>E</given-names></name><name><surname>Bennett</surname><given-names>KL</given-names></name><name><surname>Gerner</surname><given-names>C</given-names></name><etal></etal></person-group> <year>2008</year> <article-title>RNase P without RNA: identification and functional reconstitution of the human mitochondrial tRNA processing enzyme.</article-title> <source>Cell</source> <volume>135</volume> <fpage>462</fpage> <lpage>474</lpage> <pub-id pub-id-type="pmid">18984158</pub-id></element-citation></ref><ref id="pone.0028887-Holzmann2"><label>37</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Holzmann</surname><given-names>J</given-names></name><name><surname>Rossmanith</surname><given-names>W</given-names></name></person-group> <year>2009</year> <article-title>tRNA recognition, processing, and disease: hypotheses around an unorthodox type of RNase P in human mitochondria.</article-title> <source>Mitochondrion</source> <volume>9</volume> <fpage>284</fpage> <lpage>288</lpage> <pub-id pub-id-type="pmid">19376274</pub-id></element-citation></ref><ref id="pone.0028887-Yan2"><label>38</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Yan</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Sorci</surname><given-names>M</given-names></name><name><surname>Belfort</surname><given-names>G</given-names></name><name><surname>Lustbader</surname><given-names>JW</given-names></name><etal></etal></person-group> <year>2007</year> <article-title>Surface plasmon resonance and nuclear magnetic resonance studies of ABAD-Abeta interaction.</article-title> <source>Biochemistry</source> <volume>46</volume> <fpage>1724</fpage> <lpage>1731</lpage> <pub-id pub-id-type="pmid">17253767</pub-id></element-citation></ref><ref id="pone.0028887-Oppermann1"><label>39</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Oppermann</surname><given-names>UC</given-names></name><name><surname>Salim</surname><given-names>S</given-names></name><name><surname>Tjernberg</surname><given-names>LO</given-names></name><name><surname>Terenius</surname><given-names>L</given-names></name><name><surname>Jornvall</surname><given-names>H</given-names></name></person-group> <year>1999</year> <article-title>Binding of amyloid beta-peptide to mitochondrial hydroxyacyl-CoA dehydrogenase (ERAB): regulation of an SDR enzyme activity with implications for apoptosis in Alzheimer's disease.</article-title> <source>FEBS Lett</source> <volume>451</volume> <fpage>238</fpage> <lpage>242</lpage> <pub-id pub-id-type="pmid">10371197</pub-id></element-citation></ref><ref id="pone.0028887-Chen1"><label>40</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Yan</surname><given-names>SD</given-names></name></person-group> <year>2006</year> <article-title>Mitochondrial Abeta: a potential cause of metabolic dysfunction in Alzheimer's disease.</article-title> <source>IUBMB Life</source> <volume>58</volume> <fpage>686</fpage> <lpage>694</lpage> <pub-id pub-id-type="pmid">17424907</pub-id></element-citation></ref><ref id="pone.0028887-Kissinger1"><label>41</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Kissinger</surname><given-names>CR</given-names></name><name><surname>Rejto</surname><given-names>PA</given-names></name><name><surname>Pelletier</surname><given-names>LA</given-names></name><name><surname>Thomson</surname><given-names>JA</given-names></name><name><surname>Showalter</surname><given-names>RE</given-names></name><etal></etal></person-group> <year>2004</year> <article-title>Crystal structure of human ABAD/HSD10 with a bound inhibitor: implications for design of Alzheimer's disease therapeutics.</article-title> <source>J Mol Biol</source> <volume>342</volume> <fpage>943</fpage> <lpage>952</lpage> <pub-id pub-id-type="pmid">15342248</pub-id></element-citation></ref><ref id="pone.0028887-Ferrari1"><label>42</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Ferrari</surname><given-names>A</given-names></name><name><surname>Hoerndli</surname><given-names>F</given-names></name><name><surname>Baechi</surname><given-names>T</given-names></name><name><surname>Nitsch</surname><given-names>RM</given-names></name><name><surname>Gotz</surname><given-names>J</given-names></name></person-group> <year>2003</year> <article-title>Beta-amyloid induces PHF-like tau filaments in tissue culture.</article-title> <source>J Biol Chem</source> <volume>278</volume> <fpage>40162</fpage> <lpage>40168</lpage> <pub-id pub-id-type="pmid">12893817</pub-id></element-citation></ref><ref id="pone.0028887-Hoerndli2"><label>43</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Hoerndli</surname><given-names>FJ</given-names></name><name><surname>Toigo</surname><given-names>M</given-names></name><name><surname>Schild</surname><given-names>A</given-names></name><name><surname>Gotz</surname><given-names>J</given-names></name><name><surname>Day</surname><given-names>PJ</given-names></name></person-group> <year>2004</year> <article-title>Reference genes identified in SH-SY5Y cells using custom-made gene arrays with validation by quantitative polymerase chain reaction.</article-title> <source>Anal Biochem</source> <volume>335</volume> <fpage>30</fpage> <lpage>41</lpage> <pub-id pub-id-type="pmid">15519568</pub-id></element-citation></ref><ref id="pone.0028887-Kenney1"><label>44</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Kenney</surname><given-names>AM</given-names></name><name><surname>Kocsis</surname><given-names>JD</given-names></name></person-group> <year>1998</year> <article-title>Peripheral axotomy induces long-term c-Jun amino-terminal kinase-1 activation and activator protein-1 binding activity by c-Jun and junD in adult rat dorsal root ganglia In vivo.</article-title> <source>J Neurosci</source> <volume>18</volume> <fpage>1318</fpage> <lpage>1328</lpage> <pub-id pub-id-type="pmid">9454841</pub-id></element-citation></ref><ref id="pone.0028887-Budd1"><label>45</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Budd</surname><given-names>SL</given-names></name><name><surname>Castilho</surname><given-names>RF</given-names></name><name><surname>Nicholls</surname><given-names>DG</given-names></name></person-group> <year>1997</year> <article-title>Mitochondrial membrane potential and hydroethidine-monitored superoxide generation in cultured cerebellar granule cells.</article-title> <source>FEBS Lett</source> <volume>415</volume> <fpage>21</fpage> <lpage>24</lpage> <pub-id pub-id-type="pmid">9326361</pub-id></element-citation></ref><ref id="pone.0028887-Marques1"><label>46</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Marques</surname><given-names>AT</given-names></name><name><surname>Fernandes</surname><given-names>PA</given-names></name><name><surname>Ramos</surname><given-names>MJ</given-names></name></person-group> <year>2008</year> <article-title>Molecular dynamics simulations of the amyloid-beta binding alcohol dehydrogenase (ABAD) enzyme.</article-title> <source>Bioorg Med Chem</source> <volume>16</volume> <fpage>9511</fpage> <lpage>9518</lpage> <pub-id pub-id-type="pmid">18835182</pub-id></element-citation></ref><ref id="pone.0028887-Muirhead1"><label>47</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Muirhead</surname><given-names>KE</given-names></name><name><surname>Froemming</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Musilek</surname><given-names>K</given-names></name><name><surname>Conway</surname><given-names>SJ</given-names></name><etal></etal></person-group> <year>2010</year> <article-title>(-)-CHANA, a fluorogenic probe for detecting amyloid binding alcohol dehydrogenase HSD10 activity in living cells.</article-title> <source>ACS Chem Biol</source> <volume>5</volume> <fpage>1105</fpage> <lpage>1114</lpage> <pub-id pub-id-type="pmid">20836522</pub-id></element-citation></ref><ref id="pone.0028887-Borger1"><label>48</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Borger</surname><given-names>E</given-names></name><name><surname>Aitken</surname><given-names>L</given-names></name><name><surname>Muirhead</surname><given-names>KE</given-names></name><name><surname>Allen</surname><given-names>ZE</given-names></name><name><surname>Ainge</surname><given-names>JA</given-names></name><etal></etal></person-group> <year>2011</year> <article-title>Mitochondrial beta-amyloid in Alzheimer's disease.</article-title> <source>Biochem Soc Trans</source> <volume>39</volume> <fpage>868</fpage> <lpage>873</lpage> <pub-id pub-id-type="pmid">21787315</pub-id></element-citation></ref><ref id="pone.0028887-Rhein2"><label>49</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Rhein</surname><given-names>V</given-names></name><name><surname>Baysang</surname><given-names>G</given-names></name><name><surname>Rao</surname><given-names>S</given-names></name><name><surname>Meier</surname><given-names>F</given-names></name><name><surname>Bonert</surname><given-names>A</given-names></name><etal></etal></person-group> <year>2009</year> <article-title>Amyloid-beta Leads to Impaired Cellular Respiration, Energy Production and Mitochondrial Electron Chain Complex Activities in Human Neuroblastoma Cells.</article-title> <source>Cell Mol Neurobiol</source> </element-citation></ref><ref id="pone.0028887-Afanasev1"><label>50</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Afanas'ev</surname><given-names>I</given-names></name></person-group> <year>2010</year> <article-title>Signaling of reactive oxygen and nitrogen species in Diabetes mellitus.</article-title> <source>Oxid Med Cell Longev</source> <volume>3</volume> <fpage>361</fpage> <lpage>373</lpage> <pub-id pub-id-type="pmid">21311214</pub-id></element-citation></ref><ref id="pone.0028887-Dumont1"><label>51</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Dumont</surname><given-names>M</given-names></name><name><surname>Beal</surname><given-names>MF</given-names></name></person-group> <year>2010</year> <article-title>Neuroprotective strategies involving ROS in Alzheimer disease.</article-title> <source>Free Radic Biol Med</source> </element-citation></ref><ref id="pone.0028887-Lim1"><label>52</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Lim</surname><given-names>Y-A</given-names></name><name><surname>Rhein</surname><given-names>V</given-names></name><name><surname>Baysang</surname><given-names>G</given-names></name><name><surname>Meier</surname><given-names>F</given-names></name><name><surname>Poljak</surname><given-names>A</given-names></name><etal></etal></person-group> <year>2010</year> <article-title>Abeta and human amylin share a common toxicity pathway via mitochondrial dysfunction.</article-title> <source>Proteomics</source> <volume>10</volume> <fpage>1621</fpage> <lpage>1633</lpage> <pub-id pub-id-type="pmid">20186753</pub-id></element-citation></ref><ref id="pone.0028887-Moreira1"><label>53</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Moreira</surname><given-names>PI</given-names></name><name><surname>Duarte</surname><given-names>AI</given-names></name><name><surname>Santos</surname><given-names>MS</given-names></name><name><surname>Rego</surname><given-names>AC</given-names></name><name><surname>Oliveira</surname><given-names>CR</given-names></name></person-group> <year>2009</year> <article-title>An integrative view of the role of oxidative stress, mitochondria and insulin in Alzheimer's disease.</article-title> <source>J Alzheimers Dis</source> <volume>16</volume> <fpage>741</fpage> <lpage>761</lpage> <pub-id pub-id-type="pmid">19387110</pub-id></element-citation></ref><ref id="pone.0028887-Winton1"><label>54</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Winton</surname><given-names>MJ</given-names></name><name><surname>Lee</surname><given-names>EB</given-names></name><name><surname>Sun</surname><given-names>E</given-names></name><name><surname>Wong</surname><given-names>MM</given-names></name><name><surname>Leight</surname><given-names>S</given-names></name><etal></etal></person-group> <year>2011</year> <article-title>Intraneuronal APP, Not Free A{beta} Peptides in 3xTg-AD Mice: Implications for Tau versus A{beta}-Mediated Alzheimer Neurodegeneration.</article-title> <source>J Neurosci</source> <volume>31</volume> <fpage>7691</fpage> <lpage>7699</lpage> <pub-id pub-id-type="pmid">21613482</pub-id></element-citation></ref><ref id="pone.0028887-GarciaSegura1"><label>55</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Garcia-Segura</surname><given-names>LM</given-names></name><name><surname>Azcoitia</surname><given-names>I</given-names></name><name><surname>DonCarlos</surname><given-names>LL</given-names></name></person-group> <year>2001</year> <article-title>Neuroprotection by estradiol.</article-title> <source>Prog Neurobiol</source> <volume>63</volume> <fpage>29</fpage> <lpage>60</lpage> <pub-id pub-id-type="pmid">11040417</pub-id></element-citation></ref><ref id="pone.0028887-Powell1"><label>56</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Powell</surname><given-names>AJ</given-names></name><name><surname>Read</surname><given-names>JA</given-names></name><name><surname>Banfield</surname><given-names>MJ</given-names></name><name><surname>Gunn-Moore</surname><given-names>F</given-names></name><name><surname>Yan</surname><given-names>SD</given-names></name><etal></etal></person-group> <year>2000</year> <article-title>Recognition of structurally diverse substrates by type II 3-hydroxyacyl-CoA dehydrogenase (HADH II)/amyloid-beta binding alcohol dehydrogenase (ABAD).</article-title> <source>J Mol Biol</source> <volume>303</volume> <fpage>311</fpage> <lpage>327</lpage> <pub-id pub-id-type="pmid">11023795</pub-id></element-citation></ref><ref id="pone.0028887-He4"><label>57</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>He</surname><given-names>XY</given-names></name><name><surname>Wen</surname><given-names>GY</given-names></name><name><surname>Merz</surname><given-names>G</given-names></name><name><surname>Lin</surname><given-names>D</given-names></name><name><surname>Yang</surname><given-names>YZ</given-names></name><etal></etal></person-group> <year>2002</year> <article-title>Abundant type 10 17 beta-hydroxysteroid dehydrogenase in the hippocampus of mouse Alzheimer's disease model.</article-title> <source>Brain Res Mol Brain Res</source> <volume>99</volume> <fpage>46</fpage> <lpage>53</lpage> <pub-id pub-id-type="pmid">11869808</pub-id></element-citation></ref><ref id="pone.0028887-Marques2"><label>58</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Marques</surname><given-names>AT</given-names></name><name><surname>Antunes</surname><given-names>A</given-names></name><name><surname>Fernandes</surname><given-names>PA</given-names></name><name><surname>Ramos</surname><given-names>MJ</given-names></name></person-group> <year>2006</year> <article-title>Comparative evolutionary genomics of the HADH2 gene encoding Abeta-binding alcohol dehydrogenase/17beta-hydroxysteroid dehydrogenase type 10 (ABAD/HSD10).</article-title> <source>BMC Genomics</source> <volume>7</volume> <fpage>202</fpage> <pub-id pub-id-type="pmid">16899120</pub-id></element-citation></ref><ref id="pone.0028887-Gotz2"><label>59</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Gotz</surname><given-names>J</given-names></name><name><surname>Ittner</surname><given-names>LM</given-names></name><name><surname>Lim</surname><given-names>YA</given-names></name></person-group> <year>2009</year> <article-title>Common features between diabetes mellitus and Alzheimer's disease.</article-title> <source>Cell Mol Life Sci</source> <volume>66</volume> <fpage>1321</fpage> <lpage>1325</lpage> <pub-id pub-id-type="pmid">19266159</pub-id></element-citation></ref><ref id="pone.0028887-Gotz3"><label>60</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Gotz</surname><given-names>J</given-names></name><name><surname>Eckert</surname><given-names>A</given-names></name><name><surname>Matamales</surname><given-names>M</given-names></name><name><surname>Ittner</surname><given-names>LM</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name></person-group> <year>2011</year> <article-title>Modes of Abeta toxicity in Alzheimer's disease.</article-title> <source>Cell Mol Life Sci</source> <volume>68</volume> <fpage>3359</fpage> <lpage>3375</lpage> <pub-id pub-id-type="pmid">21706148</pub-id></element-citation></ref><ref id="pone.0028887-Patti1"><label>61</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Patti</surname><given-names>ME</given-names></name><name><surname>Corvera</surname><given-names>S</given-names></name></person-group> <year>2010</year> <article-title>The role of mitochondria in the pathogenesis of type 2 diabetes.</article-title> <source>Endocr Rev</source> <volume>31</volume> <fpage>364</fpage> <lpage>395</lpage> <pub-id pub-id-type="pmid">20156986</pub-id></element-citation></ref><ref id="pone.0028887-Lim2"><label>62</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Lim</surname><given-names>YA</given-names></name><name><surname>Ittner</surname><given-names>LM</given-names></name><name><surname>Lim</surname><given-names>YL</given-names></name><name><surname>Gotz</surname><given-names>J</given-names></name></person-group> <year>2008</year> <article-title>Human but not rat amylin shares neurotoxic properties with Abeta42 in long-term hippocampal and cortical cultures.</article-title> <source>FEBS Lett</source> <volume>582</volume> <fpage>2188</fpage> <lpage>2194</lpage> <pub-id pub-id-type="pmid">18486611</pub-id></element-citation></ref><ref id="pone.0028887-Bucciantini1"><label>63</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Bucciantini</surname><given-names>M</given-names></name><name><surname>Giannoni</surname><given-names>E</given-names></name><name><surname>Chiti</surname><given-names>F</given-names></name><name><surname>Baroni</surname><given-names>F</given-names></name><name><surname>Formigli</surname><given-names>L</given-names></name><etal></etal></person-group> <year>2002</year> <article-title>Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases.</article-title> <source>Nature</source> <volume>416</volume> <fpage>507</fpage> <lpage>511</lpage> <pub-id pub-id-type="pmid">11932737</pub-id></element-citation></ref><ref id="pone.0028887-Bernas1"><label>64</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Bernas</surname><given-names>T</given-names></name><name><surname>Dobrucki</surname><given-names>J</given-names></name></person-group> <year>2002</year> <article-title>Mitochondrial and nonmitochondrial reduction of MTT: interaction of MTT with TMRE, JC-1, and NAO mitochondrial fluorescent probes.</article-title> <source>Cytometry</source> <volume>47</volume> <fpage>236</fpage> <lpage>242</lpage> <pub-id pub-id-type="pmid">11933013</pub-id></element-citation></ref><ref id="pone.0028887-Lobner1"><label>65</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Lobner</surname><given-names>D</given-names></name></person-group> <year>2000</year> <article-title>Comparison of the LDH and MTT assays for quantifying cell death: validity for neuronal apoptosis?</article-title> <source>J Neurosci Methods</source> <volume>96</volume> <fpage>147</fpage> <lpage>152</lpage> <pub-id pub-id-type="pmid">10720679</pub-id></element-citation></ref><ref id="pone.0028887-Yao4"><label>66</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Yao</surname><given-names>J</given-names></name><name><surname>Irwin</surname><given-names>RW</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Nilsen</surname><given-names>J</given-names></name><name><surname>Hamilton</surname><given-names>RT</given-names></name><etal></etal></person-group> <year>2009</year> <article-title>Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease.</article-title> <source>Proc Natl Acad Sci U S A</source> <volume>106</volume> <fpage>14670</fpage> <lpage>14675</lpage> <pub-id pub-id-type="pmid">19667196</pub-id></element-citation></ref><ref id="pone.0028887-Seo1"><label>67</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Seo</surname><given-names>JS</given-names></name><name><surname>Lee</surname><given-names>KW</given-names></name><name><surname>Kim</surname><given-names>TK</given-names></name><name><surname>Baek</surname><given-names>IS</given-names></name><name><surname>Im</surname><given-names>JY</given-names></name><etal></etal></person-group> <year>2011</year> <article-title>Behavioral stress causes mitochondrial dysfunction via ABAD up-regulation and aggravates plaque pathology in the brain of a mouse model of Alzheimer disease.</article-title> <source>Free Radic Biol Med</source> <volume>50</volume> <fpage>1526</fpage> <lpage>1535</lpage> <pub-id pub-id-type="pmid">21382475</pub-id></element-citation></ref><ref id="pone.0028887-Yan3"><label>68</label><element-citation publication-type="journal"> <person-group person-group-type="author"><name><surname>Yan</surname><given-names>SD</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>A</given-names></name><name><surname>Fu</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><etal></etal></person-group> <year>1999</year> <article-title>Role of ERAB/L-3-hydroxyacyl-coenzyme A dehydrogenase type II activity in Abeta-induced cytotoxicity.</article-title> <source>J Biol Chem</source> <volume>274</volume> <fpage>2145</fpage> <lpage>2156</lpage> <pub-id pub-id-type="pmid">9890977</pub-id></element-citation></ref></ref-list></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002C320 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 002C320 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.33. |  |